Contact Information
Call us at: (614) 722-3696
Fax us at: (614) 722-3680
Center for Vaccines and ImmunityAbigail Wexner Research Institute700 Children’s Drive, WA4012Columbus, OH 43205 (map)
Learn more about Mark E. Peeples
Research
Lab(s)
Center for Vaccines and Immunity
The Peeples’ lab is working to understand respiratory syncytial virus (RSV), the most prominent cause of hospitalization for children. Starting with “progenitor” cells that they isolate from airways, they develop mucus-producing and cilia-waving cells. The RSV attachment glycoprotein (G) attaches RSV to ciliated cells and they have identified a virus receptor on these cells. After attaching to the cell, the viral membrane fuses with the target cell membrane, spilling the viral genome into the cell to initiate infection. They are studying both the attachment by the G protein and the fusion, driven by the RSV fusion (F) protein. F dramatically refolds to reach out to the cell membrane, grab it, and continuing to refold, pulling the two membranes together and causing them to fuse. They are working to identify the “trigger” point on the RSV F protein and what interaction initiates this refolding. In collaboration with six other labs, they are developing novel live attenuated vaccine candidates for RSV, the most common cause of hospitalization for young children in the US. They recently published their first candidate RSV vaccine, finding that a low dose of vaccine efficiently induced antibodies and was highly protective in animals. When COVID19 appeared, the Peeples’ lab shifted much of their effort toward understanding its cause, SARS-CoV-2, and how to stop it. They have made progress in understanding how the virus initiates infection of ciliated airway cells, and measured the amounts, effectiveness, and lifespan of serum antibodies to its “Spike” protein, in infected and vaccinated people. Working with colleagues at OSU and at NCH, they have developed several vaccine candidates that use the measles vaccine virus to deliver the Spike protein to the immune system. Measles vaccine is extremely safe, cheap to produce, and protects people long-term. Maybe their candidate COVID vaccines will have some of these advantages. They do induce high levels of antibodies in mice and protect hamsters from SARS-CoV-2 infection and disease. Their group is continuing to improve their vaccine candidates by modifying the Spike protein.
View My Publications
Publications
Peeples ME. Next-generation RSV vaccines avoid flipping out. Sci Transl Med. 2022 Dec 21; 14: eade9984.
Wu Q, Kumar N, Lafuse WP, Ahumada OS, Saljoughian N, Whetstone E, Zani A, Patton AK, El Refaey M, Webb A, Pietrzak M, Yu L, Kc M, Peeples ME, Ganesan LP, Yount JS, Rajaram MVS. Influenza A virus modulates ACE2 expression and SARS-CoV-2 infectivity in human cardiomyocytes. iScience. 2022 Dec 22; 25: 105701.
Taveras J, Garcia-Maurino C, Moore-Clingenpeel M, Xu Z, Mertz S, Ye F, Chen P, Cohen SH, Cohen D, Peeples ME, Ramilo O, Mejias A. Type-III Interferons, Viral Loads, Age, and Disease Severity in Young Children with Respiratory Syncytial Virus Infection. J Infect Dis. 2022 Oct 6;
Zhang Y, Zhang LS, Dai Q, Chen P, Lu M, Kairis EL, Murugaiah V, Xu J, Shukla RK, Liang X, Zou Z, Cormet-Boyaka E, Qiu J, Peeples ME, Sharma A, He C, Li J. 5-methylcytosine (m5C) RNA modification controls the innate immune response to virus infection by regulating type I interferons. Proc Natl Acad Sci U S A. 2022 Oct 18; 119: e2123338119.
Zhang Y, Lu M, Mahesh KC, Kim E, Shamseldin MM, Ye C, Dravid P, Chamblee M, Park JG, Hall JM, Trivedi S, Chaiwatpongsakorn S, Kenny AD, Murthy SS, Sharma H, Liang X, Yount JS, Kapoor A, Martinez-Sobrido L, Dubey P, Boyaka PN, Peeples ME, Li J. A highly efficacious live attenuated mumps virus-based SARS-CoV-2 vaccine candidate expressing a six-proline stabilized prefusion spike. Proc Natl Acad Sci U S A. 2022 Aug 16; 119: e2201616119.
Lu M, Chamblee M, Zhang Y, Ye C, Dravid P, Park JG, Mahesh KC, Trivedi S, Murthy S, Sharma H, Cassady C, Chaiwatpongsakorn S, Liang X, Yount JS, Boyaka PN, Peeples ME, Martinez-Sobrido L, Kapoor A, Li J. SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern. Proc Natl Acad Sci U S A. 2022 Aug 30; 119: e2110105119.
Eltobgy MM, Zani A, Kenney AD, Estfanous S, Kim E, Badr A, Carafice C, Daily K, Whitham O, Pietrzak M, Webb A, Kawahara J, Eddy AC, Denz P, Lu M, Kc M, Peeples ME, Li J, Zhu J, Que J, Robinson R, Rosas Mejia O, Rayner RE, Hall-Stoodley L, Seveau S, Gavrilin MA, Zhang X, Thomas J, Kohlmeier JE, Suthar MS, Oltz E, Tedeschi A, Robledo-Avila FH, Partida-Sanchez S, Hemann EA, Abdelrazik E, Forero A, Nimjee SM, Boyaka PN, Cormet-Boyaka E, Yount JS, Amer AO. Caspase-4/11 exacerbates disease severity in SARS-CoV-2 infection by promoting inflammation and immunothrombosis. Proc Natl Acad Sci U S A. 2022 May 24; 119: e2202012119.
Koivisto K, Nieminen T, Mejias A, Capella Gonzalez C, Ye F, Mertz S, Peeples M, Ramilo O, Saxén H. Respiratory Syncytial Virus (RSV)-Specific Antibodies in Pregnant Women and Subsequent Risk of RSV Hospitalization in Young Infants. J Infect Dis. 2022 Apr 1; 225: 1189-1196.
Zeng C, Evans JP, King T, Zheng YM, Oltz EM, Whelan SPJ, Saif LJ, Peeples ME, Liu SL. SARS-CoV-2 spreads through cell-to-cell transmission. Proc Natl Acad Sci U S A. 2022 Jan 4; 119:
Mertz C, Glowinski R, Cohen SH, Mertz S, Ye F, Hall MW, Peeples ME, King T, Wang H, Leber AL, Sanchez PJ, Ramilo O, Mejias A. Severe Acute Respiratory Syndrome Coronavirus 2 RNAemia and Clinical Outcomes in Children With Coronavirus Disease 2019. J Infect Dis. 2022 Jan 18; 225: 208-213.
Xue M, Zhang Y, Wang H, Kairis EL, Lu M, Ahmad S, Attia Z, Harder O, Zhang Z, Wei J, Chen P, Gao Y, Peeples ME, Sharma A, Boyaka P, He C, Hur S, Niewiesk S, Li J. Viral RNA N6-methyladenosine modification modulates both innate and adaptive immune responses of human respiratory syncytial virus. PLoS Pathog. 2021 Dec; 17: e1010142.
Ernzen K, Trask AJ, Peeples ME, Garg V, Zhao MT. Human Stem Cell Models of SARS-CoV-2 Infection in the Cardiovascular System. Stem Cell Rev Rep. 2021 Dec; 17: 2107-2119.
Hussain SA, Rohlfing M, Resiliac J, Santoro J, Peeples ME, Garcin D, Grayson MH. Atopic Neutrophils Prevent Postviral Airway Disease. J Immunol. 2021 Nov 15; 207: 2589-2597.
Lu M, Zhang Y, Dravid P, Li A, Zeng C, Kc M, Trivedi S, Sharma H, Chaiwatpongsakorn S, Zani A, Kenney A, Cai C, Ye C, Liang X, Qiu J, Martinez-Sobrido L, Yount JS, Boyaka PN, Liu SL, Peeples ME, Kapoor A, Li J. A Methyltransferase-Defective Vesicular Stomatitis Virus-Based SARS-CoV-2 Vaccine Candidate Provides Complete Protection against SARS-CoV-2 Infection in Hamsters. J Virol. 2021 Sep 27; 95: e0059221.
Green G, Johnson SM, Costello H, Brakel K, Harder O, Oomens AG, Peeples ME, Moulton HM, Niewiesk S. CX3CR1 Is a Receptor for Human Respiratory Syncytial Virus in Cotton Rats. J Virol. 2021 Jul 26; 95: e0001021.
King T, Mejias A, Ramilo O, Peeples ME. The larger attachment glycoprotein of respiratory syncytial virus produced in primary human bronchial epithelial cultures reduces infectivity for cell lines. PLoS Pathog. 2021 Apr; 17: e1009469.
Lu M, Xue M, Wang HT, Kairis EL, Ahmad S, Wei J, Zhang Z, Liu Q, Zhang Y, Gao Y, Garcin D, Peeples ME, Sharma A, Hur S, He C, Li J. Nonsegmented Negative-Sense RNA Viruses Utilize N 6-Methyladenosine (m6A) as a Common Strategy To Evade Host Innate Immunity. J Virol. 2021 Apr 12; 95:
Cockerill GS, Angell RM, Bedernjak A, Chuckowree I, Fraser I, Gascon-Simorte J, Gilman MSA, Good JAD, Harland R, Johnson SM, Ludes-Meyers JH, Littler E, Lumley J, Lunn G, Mathews N, McLellan JS, Paradowski M, Peeples ME, Scott C, Tait D, Taylor G, Thom M, Thomas E, Villalonga Barber C, Ward SE, Watterson D, Williams G, Young P, Powell K. Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion. J Med Chem. 2021 Apr 8; 64: 3658-3676.
Lu M, Dravid P, Zhang Y, Trivedi S, Li A, Harder O, Kc M, Chaiwatpongsakorn S, Zani A, Kenney A, Zeng C, Cai C, Ye C, Liang X, Shimamura M, Liu SL, Mejias A, Ramilo O, Boyaka PN, Qiu J, Martinez-Sobrido L, Yount JS, Peeples ME, Kapoor A, Niewiesk S, Li J. A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike. Proc Natl Acad Sci U S A. 2021 Mar 23; 118:
Binjawadagi B, Ma Y, Binjawadagi R, Brakel K, Harder O, Peeples M, Li J, Niewiesk S. Mucosal Delivery of Recombinant Vesicular Stomatitis Virus Vectors Expressing Envelope Proteins of Respiratory Syncytial Virus Induces Protective Immunity in Cotton Rats. J Virol. 2021 Feb 24; 95:
Jenkins T, Wang R, Harder O, Xue M, Chen P, Corry J, Walker C, Teng M, Mejias A, Ramilo O, Niewiesk S, Li J, Peeples ME. A Novel Live Attenuated Respiratory Syncytial Virus Vaccine Candidate with Mutations in the L Protein SAM Binding Site and the G Protein Cleavage Site Is Protective in Cotton Rats and a Rhesus Macaque. J Virol. 2021 Jan 13; 95:
Martinez ME, Capella Gonzalez C, Huey D, Peeples ME, McCarty D, Niewiesk S. Immunogenicity and inflammatory properties of respiratory syncytial virus attachment G protein in cotton rats. PLoS One. 2021; 16: e0246770.
Xue M, Wang R, Harder O, Chen P, Lu M, Cai H, Li A, Liang X, Jennings R, La Perle K, Niewiesk S, Peeples ME, Li J. Stable Attenuation of Human Respiratory Syncytial Virus for Live Vaccines by Deletion and Insertion of Amino Acids in the Hinge Region between the mRNA Capping and Methyltransferase Domains of the Large Polymerase Protein. J Virol. 2020 Nov 23; 94:
Abraham RS, Marshall JM, Kuehn HS, Rueda CM, Gibbs A, Guider W, Stewart C, Rosenzweig SD, Wang H, Jean S, Peeples M, King T, Hunt WG, Honegger JR, Ramilo O, Mustillo PJ, Mejias A, Ardura MI, Shimamura M. Severe SARS-CoV-2 Disease In The Context Of A NF?B2 Loss-Of-Function Pathogenic Variant. J Allergy Clin Immunol. 2020 Sep 29;
Heinonen S, Velazquez VM, Ye F, Mertz S, Acero-Bedoya S, Smith B, Bunsow E, Garcia-Mauriño C, Oliva S, Cohen DM, Moore-Clingenpeel M, Peeples ME, Ramilo O, Mejias A. Immune profiles provide insights into respiratory syncytial virus disease severity in young children. Sci Transl Med. 2020 Apr 22; 12:
San-Juan-Vergara H, Peeples ME. Importance of Virus Characteristics in Respiratory Syncytial Virus-Induced Disease. Immunol Allergy Clin North Am. 2019 Aug; 39: 321-334.
Mejias A, Rodriguez-Fernandez R, Peeples ME, Ramilo O. Respiratory Syncytial Virus Vaccines: Are We Making Progress? Pediatr Infect Dis J. 2019 Jul 18;
Hussain SA, Mejias A, Ramilo O, Peeples ME, Grayson MH. Post-viral atopic airway disease: pathogenesis and potential avenues for intervention. Expert Rev Clin Immunol. 2019 Jan; 15: 49-58.
Chang SW, Wellmerling J, Zhang X, Rayner RE, Osman W, Mertz S, Amer AO, Peeples ME, Boyaka PN, Cormet-Boyaka E. The psychoactive substance of cannabis ?9-tetrahydrocannabinol (THC) negatively regulates CFTR in airway cells. Biochim Biophys Acta Gen Subj. 2018 Sep; 1862: 1988-1994.
Li A, Yu J, Lu M, Ma Y, Attia Z, Shan C, Xue M, Liang X, Craig K, Makadiya N, He JJ, Jennings R, Shi PY, Peeples ME, Liu SL, Boyaka PN, Li J. A Zika virus vaccine expressing premembrane-envelope-NS1 polyprotein. Nat Commun. 2018 Aug 3; 9: 3067.
Grieves JL, Yin Z, Garcia-Sastre A, Mena I, Peeples ME, Risman HP, Federman H, Sandoval MJ, Durbin RK, Durbin JE. A viral-vectored RSV vaccine induces long-lived humoral immunity in cotton rats. Vaccine. 2018 Jun 18; 36: 3842-3852.
View More Publications
Biography
Mark E. Peeples, PhD, is a principal investigator and member of the Center for Vaccines and Immunity at The Research Institute at Nationwide Children’s Hospital, and a professor of Pediatrics and of Molecular & Cellular Biochemistry at The Ohio State University College of Medicine. Dr. Peeples’ research focus is respiratory syncytial virus (RSV) pathogenesis and protection. RSV is the number one cause of hospitalization of children in the developed world and the cause of over 100,000 infant deaths in the developing world, as well as a major cause of death in the elderly, just behind influenza virus. His NIH-funded research is solving the mysteries of the first two steps of RSV infection, attachment and fusion. The two proteins that perform these critical functions are the major targets for vaccine development and for antiviral drug development. Dr. Peeples’ lab is also works with pharmaceutical partners in these endeavors.
Academic and Clinical Areas
Center for Vaccines and Immunity
Principal Investigator
Primary Department
Center for Vaccines and Immunity
Professional Experience
2004 - Present Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio,, Professor2004 - Present Center for Vaccines and Immunity, The Research Institute at Nationwide Children’s Hospital, Principal Investigator1993 - 2004 Department of Immunology/Microbiology, Rush Medical College and Division of Immunology, Rush University, Professor1989 - 2004 Section of Virology, Rush Medical College, Rush University, Head1990 - 1998 Department of Immunology/Microbiology, Rush Medical College, Rush University, Associate Chairman1983 - 1998 Department of Immunology/Microbiology, Rush Medical College and Division of Immunology, Graduate College, Rush University, Assistant Professor1995 - 1997 Respiratory Virus Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, Sabbatical1980 - 1993 Department of Molecular Genetics and Microbiology, University of Massachusetts Medical School, Instructor1988 - 1992 Department of Immunology/Microbiology, Rush Medical College and Division of Immunology, Graduate College, Rush University, Associate Professor1988 - 1992 Department of Immunology/Microbiology, Rush Medical College and Division of Immunology, Rush University, Associate Professor1978 - 1980 Department of Molecular Genetics and Microbiology, University of Massachusetts Medical School, Postdoctotal Fellow
Contact Information
Center for Vaccines and Immunity
Call us at: (614) 722-3696
Fax us at: (614) 722-3680
Abigail Wexner Research Institute700 Children's Drive, WA4012Columbus, OH 43205 (map)
Contact Information
Call us at: (614) 722-3696
Fax us at: (614) 722-3680
Center for Vaccines and ImmunityAbigail Wexner Research Institute700 Children’s Drive, WA4012Columbus, OH 43205 (map)
Learn more about Mark E. Peeples
Research
Lab(s)
Center for Vaccines and Immunity
The Peeples’ lab is working to understand respiratory syncytial virus (RSV), the most prominent cause of hospitalization for children. Starting with “progenitor” cells that they isolate from airways, they develop mucus-producing and cilia-waving cells. The RSV attachment glycoprotein (G) attaches RSV to ciliated cells and they have identified a virus receptor on these cells. After attaching to the cell, the viral membrane fuses with the target cell membrane, spilling the viral genome into the cell to initiate infection. They are studying both the attachment by the G protein and the fusion, driven by the RSV fusion (F) protein. F dramatically refolds to reach out to the cell membrane, grab it, and continuing to refold, pulling the two membranes together and causing them to fuse. They are working to identify the “trigger” point on the RSV F protein and what interaction initiates this refolding. In collaboration with six other labs, they are developing novel live attenuated vaccine candidates for RSV, the most common cause of hospitalization for young children in the US. They recently published their first candidate RSV vaccine, finding that a low dose of vaccine efficiently induced antibodies and was highly protective in animals. When COVID19 appeared, the Peeples’ lab shifted much of their effort toward understanding its cause, SARS-CoV-2, and how to stop it. They have made progress in understanding how the virus initiates infection of ciliated airway cells, and measured the amounts, effectiveness, and lifespan of serum antibodies to its “Spike” protein, in infected and vaccinated people. Working with colleagues at OSU and at NCH, they have developed several vaccine candidates that use the measles vaccine virus to deliver the Spike protein to the immune system. Measles vaccine is extremely safe, cheap to produce, and protects people long-term. Maybe their candidate COVID vaccines will have some of these advantages. They do induce high levels of antibodies in mice and protect hamsters from SARS-CoV-2 infection and disease. Their group is continuing to improve their vaccine candidates by modifying the Spike protein.
View My Publications
Publications
Peeples ME. Next-generation RSV vaccines avoid flipping out. Sci Transl Med. 2022 Dec 21; 14: eade9984.
Wu Q, Kumar N, Lafuse WP, Ahumada OS, Saljoughian N, Whetstone E, Zani A, Patton AK, El Refaey M, Webb A, Pietrzak M, Yu L, Kc M, Peeples ME, Ganesan LP, Yount JS, Rajaram MVS. Influenza A virus modulates ACE2 expression and SARS-CoV-2 infectivity in human cardiomyocytes. iScience. 2022 Dec 22; 25: 105701.
Taveras J, Garcia-Maurino C, Moore-Clingenpeel M, Xu Z, Mertz S, Ye F, Chen P, Cohen SH, Cohen D, Peeples ME, Ramilo O, Mejias A. Type-III Interferons, Viral Loads, Age, and Disease Severity in Young Children with Respiratory Syncytial Virus Infection. J Infect Dis. 2022 Oct 6;
Zhang Y, Zhang LS, Dai Q, Chen P, Lu M, Kairis EL, Murugaiah V, Xu J, Shukla RK, Liang X, Zou Z, Cormet-Boyaka E, Qiu J, Peeples ME, Sharma A, He C, Li J. 5-methylcytosine (m5C) RNA modification controls the innate immune response to virus infection by regulating type I interferons. Proc Natl Acad Sci U S A. 2022 Oct 18; 119: e2123338119.
Zhang Y, Lu M, Mahesh KC, Kim E, Shamseldin MM, Ye C, Dravid P, Chamblee M, Park JG, Hall JM, Trivedi S, Chaiwatpongsakorn S, Kenny AD, Murthy SS, Sharma H, Liang X, Yount JS, Kapoor A, Martinez-Sobrido L, Dubey P, Boyaka PN, Peeples ME, Li J. A highly efficacious live attenuated mumps virus-based SARS-CoV-2 vaccine candidate expressing a six-proline stabilized prefusion spike. Proc Natl Acad Sci U S A. 2022 Aug 16; 119: e2201616119.
Lu M, Chamblee M, Zhang Y, Ye C, Dravid P, Park JG, Mahesh KC, Trivedi S, Murthy S, Sharma H, Cassady C, Chaiwatpongsakorn S, Liang X, Yount JS, Boyaka PN, Peeples ME, Martinez-Sobrido L, Kapoor A, Li J. SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern. Proc Natl Acad Sci U S A. 2022 Aug 30; 119: e2110105119.
Eltobgy MM, Zani A, Kenney AD, Estfanous S, Kim E, Badr A, Carafice C, Daily K, Whitham O, Pietrzak M, Webb A, Kawahara J, Eddy AC, Denz P, Lu M, Kc M, Peeples ME, Li J, Zhu J, Que J, Robinson R, Rosas Mejia O, Rayner RE, Hall-Stoodley L, Seveau S, Gavrilin MA, Zhang X, Thomas J, Kohlmeier JE, Suthar MS, Oltz E, Tedeschi A, Robledo-Avila FH, Partida-Sanchez S, Hemann EA, Abdelrazik E, Forero A, Nimjee SM, Boyaka PN, Cormet-Boyaka E, Yount JS, Amer AO. Caspase-4/11 exacerbates disease severity in SARS-CoV-2 infection by promoting inflammation and immunothrombosis. Proc Natl Acad Sci U S A. 2022 May 24; 119: e2202012119.
Koivisto K, Nieminen T, Mejias A, Capella Gonzalez C, Ye F, Mertz S, Peeples M, Ramilo O, Saxén H. Respiratory Syncytial Virus (RSV)-Specific Antibodies in Pregnant Women and Subsequent Risk of RSV Hospitalization in Young Infants. J Infect Dis. 2022 Apr 1; 225: 1189-1196.
Zeng C, Evans JP, King T, Zheng YM, Oltz EM, Whelan SPJ, Saif LJ, Peeples ME, Liu SL. SARS-CoV-2 spreads through cell-to-cell transmission. Proc Natl Acad Sci U S A. 2022 Jan 4; 119:
Mertz C, Glowinski R, Cohen SH, Mertz S, Ye F, Hall MW, Peeples ME, King T, Wang H, Leber AL, Sanchez PJ, Ramilo O, Mejias A. Severe Acute Respiratory Syndrome Coronavirus 2 RNAemia and Clinical Outcomes in Children With Coronavirus Disease 2019. J Infect Dis. 2022 Jan 18; 225: 208-213.
Xue M, Zhang Y, Wang H, Kairis EL, Lu M, Ahmad S, Attia Z, Harder O, Zhang Z, Wei J, Chen P, Gao Y, Peeples ME, Sharma A, Boyaka P, He C, Hur S, Niewiesk S, Li J. Viral RNA N6-methyladenosine modification modulates both innate and adaptive immune responses of human respiratory syncytial virus. PLoS Pathog. 2021 Dec; 17: e1010142.
Ernzen K, Trask AJ, Peeples ME, Garg V, Zhao MT. Human Stem Cell Models of SARS-CoV-2 Infection in the Cardiovascular System. Stem Cell Rev Rep. 2021 Dec; 17: 2107-2119.
Hussain SA, Rohlfing M, Resiliac J, Santoro J, Peeples ME, Garcin D, Grayson MH. Atopic Neutrophils Prevent Postviral Airway Disease. J Immunol. 2021 Nov 15; 207: 2589-2597.
Lu M, Zhang Y, Dravid P, Li A, Zeng C, Kc M, Trivedi S, Sharma H, Chaiwatpongsakorn S, Zani A, Kenney A, Cai C, Ye C, Liang X, Qiu J, Martinez-Sobrido L, Yount JS, Boyaka PN, Liu SL, Peeples ME, Kapoor A, Li J. A Methyltransferase-Defective Vesicular Stomatitis Virus-Based SARS-CoV-2 Vaccine Candidate Provides Complete Protection against SARS-CoV-2 Infection in Hamsters. J Virol. 2021 Sep 27; 95: e0059221.
Green G, Johnson SM, Costello H, Brakel K, Harder O, Oomens AG, Peeples ME, Moulton HM, Niewiesk S. CX3CR1 Is a Receptor for Human Respiratory Syncytial Virus in Cotton Rats. J Virol. 2021 Jul 26; 95: e0001021.
King T, Mejias A, Ramilo O, Peeples ME. The larger attachment glycoprotein of respiratory syncytial virus produced in primary human bronchial epithelial cultures reduces infectivity for cell lines. PLoS Pathog. 2021 Apr; 17: e1009469.
Lu M, Xue M, Wang HT, Kairis EL, Ahmad S, Wei J, Zhang Z, Liu Q, Zhang Y, Gao Y, Garcin D, Peeples ME, Sharma A, Hur S, He C, Li J. Nonsegmented Negative-Sense RNA Viruses Utilize N 6-Methyladenosine (m6A) as a Common Strategy To Evade Host Innate Immunity. J Virol. 2021 Apr 12; 95:
Cockerill GS, Angell RM, Bedernjak A, Chuckowree I, Fraser I, Gascon-Simorte J, Gilman MSA, Good JAD, Harland R, Johnson SM, Ludes-Meyers JH, Littler E, Lumley J, Lunn G, Mathews N, McLellan JS, Paradowski M, Peeples ME, Scott C, Tait D, Taylor G, Thom M, Thomas E, Villalonga Barber C, Ward SE, Watterson D, Williams G, Young P, Powell K. Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion. J Med Chem. 2021 Apr 8; 64: 3658-3676.
Lu M, Dravid P, Zhang Y, Trivedi S, Li A, Harder O, Kc M, Chaiwatpongsakorn S, Zani A, Kenney A, Zeng C, Cai C, Ye C, Liang X, Shimamura M, Liu SL, Mejias A, Ramilo O, Boyaka PN, Qiu J, Martinez-Sobrido L, Yount JS, Peeples ME, Kapoor A, Niewiesk S, Li J. A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike. Proc Natl Acad Sci U S A. 2021 Mar 23; 118:
Binjawadagi B, Ma Y, Binjawadagi R, Brakel K, Harder O, Peeples M, Li J, Niewiesk S. Mucosal Delivery of Recombinant Vesicular Stomatitis Virus Vectors Expressing Envelope Proteins of Respiratory Syncytial Virus Induces Protective Immunity in Cotton Rats. J Virol. 2021 Feb 24; 95:
Jenkins T, Wang R, Harder O, Xue M, Chen P, Corry J, Walker C, Teng M, Mejias A, Ramilo O, Niewiesk S, Li J, Peeples ME. A Novel Live Attenuated Respiratory Syncytial Virus Vaccine Candidate with Mutations in the L Protein SAM Binding Site and the G Protein Cleavage Site Is Protective in Cotton Rats and a Rhesus Macaque. J Virol. 2021 Jan 13; 95:
Martinez ME, Capella Gonzalez C, Huey D, Peeples ME, McCarty D, Niewiesk S. Immunogenicity and inflammatory properties of respiratory syncytial virus attachment G protein in cotton rats. PLoS One. 2021; 16: e0246770.
Xue M, Wang R, Harder O, Chen P, Lu M, Cai H, Li A, Liang X, Jennings R, La Perle K, Niewiesk S, Peeples ME, Li J. Stable Attenuation of Human Respiratory Syncytial Virus for Live Vaccines by Deletion and Insertion of Amino Acids in the Hinge Region between the mRNA Capping and Methyltransferase Domains of the Large Polymerase Protein. J Virol. 2020 Nov 23; 94:
Abraham RS, Marshall JM, Kuehn HS, Rueda CM, Gibbs A, Guider W, Stewart C, Rosenzweig SD, Wang H, Jean S, Peeples M, King T, Hunt WG, Honegger JR, Ramilo O, Mustillo PJ, Mejias A, Ardura MI, Shimamura M. Severe SARS-CoV-2 Disease In The Context Of A NF?B2 Loss-Of-Function Pathogenic Variant. J Allergy Clin Immunol. 2020 Sep 29;
Heinonen S, Velazquez VM, Ye F, Mertz S, Acero-Bedoya S, Smith B, Bunsow E, Garcia-Mauriño C, Oliva S, Cohen DM, Moore-Clingenpeel M, Peeples ME, Ramilo O, Mejias A. Immune profiles provide insights into respiratory syncytial virus disease severity in young children. Sci Transl Med. 2020 Apr 22; 12:
San-Juan-Vergara H, Peeples ME. Importance of Virus Characteristics in Respiratory Syncytial Virus-Induced Disease. Immunol Allergy Clin North Am. 2019 Aug; 39: 321-334.
Mejias A, Rodriguez-Fernandez R, Peeples ME, Ramilo O. Respiratory Syncytial Virus Vaccines: Are We Making Progress? Pediatr Infect Dis J. 2019 Jul 18;
Hussain SA, Mejias A, Ramilo O, Peeples ME, Grayson MH. Post-viral atopic airway disease: pathogenesis and potential avenues for intervention. Expert Rev Clin Immunol. 2019 Jan; 15: 49-58.
Chang SW, Wellmerling J, Zhang X, Rayner RE, Osman W, Mertz S, Amer AO, Peeples ME, Boyaka PN, Cormet-Boyaka E. The psychoactive substance of cannabis ?9-tetrahydrocannabinol (THC) negatively regulates CFTR in airway cells. Biochim Biophys Acta Gen Subj. 2018 Sep; 1862: 1988-1994.
Li A, Yu J, Lu M, Ma Y, Attia Z, Shan C, Xue M, Liang X, Craig K, Makadiya N, He JJ, Jennings R, Shi PY, Peeples ME, Liu SL, Boyaka PN, Li J. A Zika virus vaccine expressing premembrane-envelope-NS1 polyprotein. Nat Commun. 2018 Aug 3; 9: 3067.
Grieves JL, Yin Z, Garcia-Sastre A, Mena I, Peeples ME, Risman HP, Federman H, Sandoval MJ, Durbin RK, Durbin JE. A viral-vectored RSV vaccine induces long-lived humoral immunity in cotton rats. Vaccine. 2018 Jun 18; 36: 3842-3852.
View More Publications
Biography
Mark E. Peeples, PhD, is a principal investigator and member of the Center for Vaccines and Immunity at The Research Institute at Nationwide Children’s Hospital, and a professor of Pediatrics and of Molecular & Cellular Biochemistry at The Ohio State University College of Medicine. Dr. Peeples’ research focus is respiratory syncytial virus (RSV) pathogenesis and protection. RSV is the number one cause of hospitalization of children in the developed world and the cause of over 100,000 infant deaths in the developing world, as well as a major cause of death in the elderly, just behind influenza virus. His NIH-funded research is solving the mysteries of the first two steps of RSV infection, attachment and fusion. The two proteins that perform these critical functions are the major targets for vaccine development and for antiviral drug development. Dr. Peeples’ lab is also works with pharmaceutical partners in these endeavors.
Academic and Clinical Areas
Center for Vaccines and Immunity
Principal Investigator
Primary Department
Center for Vaccines and Immunity
Professional Experience
2004 - Present Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio,, Professor2004 - Present Center for Vaccines and Immunity, The Research Institute at Nationwide Children’s Hospital, Principal Investigator1993 - 2004 Department of Immunology/Microbiology, Rush Medical College and Division of Immunology, Rush University, Professor1989 - 2004 Section of Virology, Rush Medical College, Rush University, Head1990 - 1998 Department of Immunology/Microbiology, Rush Medical College, Rush University, Associate Chairman1983 - 1998 Department of Immunology/Microbiology, Rush Medical College and Division of Immunology, Graduate College, Rush University, Assistant Professor1995 - 1997 Respiratory Virus Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, Sabbatical1980 - 1993 Department of Molecular Genetics and Microbiology, University of Massachusetts Medical School, Instructor1988 - 1992 Department of Immunology/Microbiology, Rush Medical College and Division of Immunology, Graduate College, Rush University, Associate Professor1988 - 1992 Department of Immunology/Microbiology, Rush Medical College and Division of Immunology, Rush University, Associate Professor1978 - 1980 Department of Molecular Genetics and Microbiology, University of Massachusetts Medical School, Postdoctotal Fellow
Contact Information
Center for Vaccines and Immunity
Call us at: (614) 722-3696
Fax us at: (614) 722-3680
Abigail Wexner Research Institute700 Children's Drive, WA4012Columbus, OH 43205 (map)
Contact Information
Call us at: (614) 722-3696
Fax us at: (614) 722-3680
Center for Vaccines and ImmunityAbigail Wexner Research Institute700 Children’s Drive, WA4012Columbus, OH 43205 (map)
Learn more about Mark E. Peeples
Contact Information
- Call us at:
- (614) 722-3696
- Fax us at:
- (614) 722-3680
- Center for Vaccines and ImmunityAbigail Wexner Research Institute700 Children’s Drive, WA4012Columbus, OH 43205 (map)
Learn more about Mark E. Peeples
Research
Lab(s)
Center for Vaccines and Immunity
The Peeples’ lab is working to understand respiratory syncytial virus (RSV), the most prominent cause of hospitalization for children. Starting with “progenitor” cells that they isolate from airways, they develop mucus-producing and cilia-waving cells. The RSV attachment glycoprotein (G) attaches RSV to ciliated cells and they have identified a virus receptor on these cells. After attaching to the cell, the viral membrane fuses with the target cell membrane, spilling the viral genome into the cell to initiate infection. They are studying both the attachment by the G protein and the fusion, driven by the RSV fusion (F) protein. F dramatically refolds to reach out to the cell membrane, grab it, and continuing to refold, pulling the two membranes together and causing them to fuse. They are working to identify the “trigger” point on the RSV F protein and what interaction initiates this refolding. In collaboration with six other labs, they are developing novel live attenuated vaccine candidates for RSV, the most common cause of hospitalization for young children in the US. They recently published their first candidate RSV vaccine, finding that a low dose of vaccine efficiently induced antibodies and was highly protective in animals. When COVID19 appeared, the Peeples’ lab shifted much of their effort toward understanding its cause, SARS-CoV-2, and how to stop it. They have made progress in understanding how the virus initiates infection of ciliated airway cells, and measured the amounts, effectiveness, and lifespan of serum antibodies to its “Spike” protein, in infected and vaccinated people. Working with colleagues at OSU and at NCH, they have developed several vaccine candidates that use the measles vaccine virus to deliver the Spike protein to the immune system. Measles vaccine is extremely safe, cheap to produce, and protects people long-term. Maybe their candidate COVID vaccines will have some of these advantages. They do induce high levels of antibodies in mice and protect hamsters from SARS-CoV-2 infection and disease. Their group is continuing to improve their vaccine candidates by modifying the Spike protein.
View My Publications
Publications
Peeples ME. Next-generation RSV vaccines avoid flipping out. Sci Transl Med. 2022 Dec 21; 14: eade9984.
Wu Q, Kumar N, Lafuse WP, Ahumada OS, Saljoughian N, Whetstone E, Zani A, Patton AK, El Refaey M, Webb A, Pietrzak M, Yu L, Kc M, Peeples ME, Ganesan LP, Yount JS, Rajaram MVS. Influenza A virus modulates ACE2 expression and SARS-CoV-2 infectivity in human cardiomyocytes. iScience. 2022 Dec 22; 25: 105701.
Taveras J, Garcia-Maurino C, Moore-Clingenpeel M, Xu Z, Mertz S, Ye F, Chen P, Cohen SH, Cohen D, Peeples ME, Ramilo O, Mejias A. Type-III Interferons, Viral Loads, Age, and Disease Severity in Young Children with Respiratory Syncytial Virus Infection. J Infect Dis. 2022 Oct 6;
Zhang Y, Zhang LS, Dai Q, Chen P, Lu M, Kairis EL, Murugaiah V, Xu J, Shukla RK, Liang X, Zou Z, Cormet-Boyaka E, Qiu J, Peeples ME, Sharma A, He C, Li J. 5-methylcytosine (m5C) RNA modification controls the innate immune response to virus infection by regulating type I interferons. Proc Natl Acad Sci U S A. 2022 Oct 18; 119: e2123338119.
Zhang Y, Lu M, Mahesh KC, Kim E, Shamseldin MM, Ye C, Dravid P, Chamblee M, Park JG, Hall JM, Trivedi S, Chaiwatpongsakorn S, Kenny AD, Murthy SS, Sharma H, Liang X, Yount JS, Kapoor A, Martinez-Sobrido L, Dubey P, Boyaka PN, Peeples ME, Li J. A highly efficacious live attenuated mumps virus-based SARS-CoV-2 vaccine candidate expressing a six-proline stabilized prefusion spike. Proc Natl Acad Sci U S A. 2022 Aug 16; 119: e2201616119.
Lu M, Chamblee M, Zhang Y, Ye C, Dravid P, Park JG, Mahesh KC, Trivedi S, Murthy S, Sharma H, Cassady C, Chaiwatpongsakorn S, Liang X, Yount JS, Boyaka PN, Peeples ME, Martinez-Sobrido L, Kapoor A, Li J. SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern. Proc Natl Acad Sci U S A. 2022 Aug 30; 119: e2110105119.
Eltobgy MM, Zani A, Kenney AD, Estfanous S, Kim E, Badr A, Carafice C, Daily K, Whitham O, Pietrzak M, Webb A, Kawahara J, Eddy AC, Denz P, Lu M, Kc M, Peeples ME, Li J, Zhu J, Que J, Robinson R, Rosas Mejia O, Rayner RE, Hall-Stoodley L, Seveau S, Gavrilin MA, Zhang X, Thomas J, Kohlmeier JE, Suthar MS, Oltz E, Tedeschi A, Robledo-Avila FH, Partida-Sanchez S, Hemann EA, Abdelrazik E, Forero A, Nimjee SM, Boyaka PN, Cormet-Boyaka E, Yount JS, Amer AO. Caspase-4/11 exacerbates disease severity in SARS-CoV-2 infection by promoting inflammation and immunothrombosis. Proc Natl Acad Sci U S A. 2022 May 24; 119: e2202012119.
Koivisto K, Nieminen T, Mejias A, Capella Gonzalez C, Ye F, Mertz S, Peeples M, Ramilo O, Saxén H. Respiratory Syncytial Virus (RSV)-Specific Antibodies in Pregnant Women and Subsequent Risk of RSV Hospitalization in Young Infants. J Infect Dis. 2022 Apr 1; 225: 1189-1196.
Zeng C, Evans JP, King T, Zheng YM, Oltz EM, Whelan SPJ, Saif LJ, Peeples ME, Liu SL. SARS-CoV-2 spreads through cell-to-cell transmission. Proc Natl Acad Sci U S A. 2022 Jan 4; 119:
Mertz C, Glowinski R, Cohen SH, Mertz S, Ye F, Hall MW, Peeples ME, King T, Wang H, Leber AL, Sanchez PJ, Ramilo O, Mejias A. Severe Acute Respiratory Syndrome Coronavirus 2 RNAemia and Clinical Outcomes in Children With Coronavirus Disease 2019. J Infect Dis. 2022 Jan 18; 225: 208-213.
Xue M, Zhang Y, Wang H, Kairis EL, Lu M, Ahmad S, Attia Z, Harder O, Zhang Z, Wei J, Chen P, Gao Y, Peeples ME, Sharma A, Boyaka P, He C, Hur S, Niewiesk S, Li J. Viral RNA N6-methyladenosine modification modulates both innate and adaptive immune responses of human respiratory syncytial virus. PLoS Pathog. 2021 Dec; 17: e1010142.
Ernzen K, Trask AJ, Peeples ME, Garg V, Zhao MT. Human Stem Cell Models of SARS-CoV-2 Infection in the Cardiovascular System. Stem Cell Rev Rep. 2021 Dec; 17: 2107-2119.
Hussain SA, Rohlfing M, Resiliac J, Santoro J, Peeples ME, Garcin D, Grayson MH. Atopic Neutrophils Prevent Postviral Airway Disease. J Immunol. 2021 Nov 15; 207: 2589-2597.
Lu M, Zhang Y, Dravid P, Li A, Zeng C, Kc M, Trivedi S, Sharma H, Chaiwatpongsakorn S, Zani A, Kenney A, Cai C, Ye C, Liang X, Qiu J, Martinez-Sobrido L, Yount JS, Boyaka PN, Liu SL, Peeples ME, Kapoor A, Li J. A Methyltransferase-Defective Vesicular Stomatitis Virus-Based SARS-CoV-2 Vaccine Candidate Provides Complete Protection against SARS-CoV-2 Infection in Hamsters. J Virol. 2021 Sep 27; 95: e0059221.
Green G, Johnson SM, Costello H, Brakel K, Harder O, Oomens AG, Peeples ME, Moulton HM, Niewiesk S. CX3CR1 Is a Receptor for Human Respiratory Syncytial Virus in Cotton Rats. J Virol. 2021 Jul 26; 95: e0001021.
King T, Mejias A, Ramilo O, Peeples ME. The larger attachment glycoprotein of respiratory syncytial virus produced in primary human bronchial epithelial cultures reduces infectivity for cell lines. PLoS Pathog. 2021 Apr; 17: e1009469.
Lu M, Xue M, Wang HT, Kairis EL, Ahmad S, Wei J, Zhang Z, Liu Q, Zhang Y, Gao Y, Garcin D, Peeples ME, Sharma A, Hur S, He C, Li J. Nonsegmented Negative-Sense RNA Viruses Utilize N 6-Methyladenosine (m6A) as a Common Strategy To Evade Host Innate Immunity. J Virol. 2021 Apr 12; 95:
Cockerill GS, Angell RM, Bedernjak A, Chuckowree I, Fraser I, Gascon-Simorte J, Gilman MSA, Good JAD, Harland R, Johnson SM, Ludes-Meyers JH, Littler E, Lumley J, Lunn G, Mathews N, McLellan JS, Paradowski M, Peeples ME, Scott C, Tait D, Taylor G, Thom M, Thomas E, Villalonga Barber C, Ward SE, Watterson D, Williams G, Young P, Powell K. Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion. J Med Chem. 2021 Apr 8; 64: 3658-3676.
Lu M, Dravid P, Zhang Y, Trivedi S, Li A, Harder O, Kc M, Chaiwatpongsakorn S, Zani A, Kenney A, Zeng C, Cai C, Ye C, Liang X, Shimamura M, Liu SL, Mejias A, Ramilo O, Boyaka PN, Qiu J, Martinez-Sobrido L, Yount JS, Peeples ME, Kapoor A, Niewiesk S, Li J. A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike. Proc Natl Acad Sci U S A. 2021 Mar 23; 118:
Binjawadagi B, Ma Y, Binjawadagi R, Brakel K, Harder O, Peeples M, Li J, Niewiesk S. Mucosal Delivery of Recombinant Vesicular Stomatitis Virus Vectors Expressing Envelope Proteins of Respiratory Syncytial Virus Induces Protective Immunity in Cotton Rats. J Virol. 2021 Feb 24; 95:
Jenkins T, Wang R, Harder O, Xue M, Chen P, Corry J, Walker C, Teng M, Mejias A, Ramilo O, Niewiesk S, Li J, Peeples ME. A Novel Live Attenuated Respiratory Syncytial Virus Vaccine Candidate with Mutations in the L Protein SAM Binding Site and the G Protein Cleavage Site Is Protective in Cotton Rats and a Rhesus Macaque. J Virol. 2021 Jan 13; 95:
Martinez ME, Capella Gonzalez C, Huey D, Peeples ME, McCarty D, Niewiesk S. Immunogenicity and inflammatory properties of respiratory syncytial virus attachment G protein in cotton rats. PLoS One. 2021; 16: e0246770.
Xue M, Wang R, Harder O, Chen P, Lu M, Cai H, Li A, Liang X, Jennings R, La Perle K, Niewiesk S, Peeples ME, Li J. Stable Attenuation of Human Respiratory Syncytial Virus for Live Vaccines by Deletion and Insertion of Amino Acids in the Hinge Region between the mRNA Capping and Methyltransferase Domains of the Large Polymerase Protein. J Virol. 2020 Nov 23; 94:
Abraham RS, Marshall JM, Kuehn HS, Rueda CM, Gibbs A, Guider W, Stewart C, Rosenzweig SD, Wang H, Jean S, Peeples M, King T, Hunt WG, Honegger JR, Ramilo O, Mustillo PJ, Mejias A, Ardura MI, Shimamura M. Severe SARS-CoV-2 Disease In The Context Of A NF?B2 Loss-Of-Function Pathogenic Variant. J Allergy Clin Immunol. 2020 Sep 29;
Heinonen S, Velazquez VM, Ye F, Mertz S, Acero-Bedoya S, Smith B, Bunsow E, Garcia-Mauriño C, Oliva S, Cohen DM, Moore-Clingenpeel M, Peeples ME, Ramilo O, Mejias A. Immune profiles provide insights into respiratory syncytial virus disease severity in young children. Sci Transl Med. 2020 Apr 22; 12:
San-Juan-Vergara H, Peeples ME. Importance of Virus Characteristics in Respiratory Syncytial Virus-Induced Disease. Immunol Allergy Clin North Am. 2019 Aug; 39: 321-334.
Mejias A, Rodriguez-Fernandez R, Peeples ME, Ramilo O. Respiratory Syncytial Virus Vaccines: Are We Making Progress? Pediatr Infect Dis J. 2019 Jul 18;
Hussain SA, Mejias A, Ramilo O, Peeples ME, Grayson MH. Post-viral atopic airway disease: pathogenesis and potential avenues for intervention. Expert Rev Clin Immunol. 2019 Jan; 15: 49-58.
Chang SW, Wellmerling J, Zhang X, Rayner RE, Osman W, Mertz S, Amer AO, Peeples ME, Boyaka PN, Cormet-Boyaka E. The psychoactive substance of cannabis ?9-tetrahydrocannabinol (THC) negatively regulates CFTR in airway cells. Biochim Biophys Acta Gen Subj. 2018 Sep; 1862: 1988-1994.
Li A, Yu J, Lu M, Ma Y, Attia Z, Shan C, Xue M, Liang X, Craig K, Makadiya N, He JJ, Jennings R, Shi PY, Peeples ME, Liu SL, Boyaka PN, Li J. A Zika virus vaccine expressing premembrane-envelope-NS1 polyprotein. Nat Commun. 2018 Aug 3; 9: 3067.
Grieves JL, Yin Z, Garcia-Sastre A, Mena I, Peeples ME, Risman HP, Federman H, Sandoval MJ, Durbin RK, Durbin JE. A viral-vectored RSV vaccine induces long-lived humoral immunity in cotton rats. Vaccine. 2018 Jun 18; 36: 3842-3852.
View More Publications
Research
Lab(s)
Center for Vaccines and Immunity
The Peeples’ lab is working to understand respiratory syncytial virus (RSV), the most prominent cause of hospitalization for children. Starting with “progenitor” cells that they isolate from airways, they develop mucus-producing and cilia-waving cells. The RSV attachment glycoprotein (G) attaches RSV to ciliated cells and they have identified a virus receptor on these cells. After attaching to the cell, the viral membrane fuses with the target cell membrane, spilling the viral genome into the cell to initiate infection. They are studying both the attachment by the G protein and the fusion, driven by the RSV fusion (F) protein. F dramatically refolds to reach out to the cell membrane, grab it, and continuing to refold, pulling the two membranes together and causing them to fuse. They are working to identify the “trigger” point on the RSV F protein and what interaction initiates this refolding. In collaboration with six other labs, they are developing novel live attenuated vaccine candidates for RSV, the most common cause of hospitalization for young children in the US. They recently published their first candidate RSV vaccine, finding that a low dose of vaccine efficiently induced antibodies and was highly protective in animals. When COVID19 appeared, the Peeples’ lab shifted much of their effort toward understanding its cause, SARS-CoV-2, and how to stop it. They have made progress in understanding how the virus initiates infection of ciliated airway cells, and measured the amounts, effectiveness, and lifespan of serum antibodies to its “Spike” protein, in infected and vaccinated people. Working with colleagues at OSU and at NCH, they have developed several vaccine candidates that use the measles vaccine virus to deliver the Spike protein to the immune system. Measles vaccine is extremely safe, cheap to produce, and protects people long-term. Maybe their candidate COVID vaccines will have some of these advantages. They do induce high levels of antibodies in mice and protect hamsters from SARS-CoV-2 infection and disease. Their group is continuing to improve their vaccine candidates by modifying the Spike protein.
View My Publications
Publications
Peeples ME. Next-generation RSV vaccines avoid flipping out. Sci Transl Med. 2022 Dec 21; 14: eade9984.
Wu Q, Kumar N, Lafuse WP, Ahumada OS, Saljoughian N, Whetstone E, Zani A, Patton AK, El Refaey M, Webb A, Pietrzak M, Yu L, Kc M, Peeples ME, Ganesan LP, Yount JS, Rajaram MVS. Influenza A virus modulates ACE2 expression and SARS-CoV-2 infectivity in human cardiomyocytes. iScience. 2022 Dec 22; 25: 105701.
Taveras J, Garcia-Maurino C, Moore-Clingenpeel M, Xu Z, Mertz S, Ye F, Chen P, Cohen SH, Cohen D, Peeples ME, Ramilo O, Mejias A. Type-III Interferons, Viral Loads, Age, and Disease Severity in Young Children with Respiratory Syncytial Virus Infection. J Infect Dis. 2022 Oct 6;
Zhang Y, Zhang LS, Dai Q, Chen P, Lu M, Kairis EL, Murugaiah V, Xu J, Shukla RK, Liang X, Zou Z, Cormet-Boyaka E, Qiu J, Peeples ME, Sharma A, He C, Li J. 5-methylcytosine (m5C) RNA modification controls the innate immune response to virus infection by regulating type I interferons. Proc Natl Acad Sci U S A. 2022 Oct 18; 119: e2123338119.
Zhang Y, Lu M, Mahesh KC, Kim E, Shamseldin MM, Ye C, Dravid P, Chamblee M, Park JG, Hall JM, Trivedi S, Chaiwatpongsakorn S, Kenny AD, Murthy SS, Sharma H, Liang X, Yount JS, Kapoor A, Martinez-Sobrido L, Dubey P, Boyaka PN, Peeples ME, Li J. A highly efficacious live attenuated mumps virus-based SARS-CoV-2 vaccine candidate expressing a six-proline stabilized prefusion spike. Proc Natl Acad Sci U S A. 2022 Aug 16; 119: e2201616119.
Lu M, Chamblee M, Zhang Y, Ye C, Dravid P, Park JG, Mahesh KC, Trivedi S, Murthy S, Sharma H, Cassady C, Chaiwatpongsakorn S, Liang X, Yount JS, Boyaka PN, Peeples ME, Martinez-Sobrido L, Kapoor A, Li J. SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern. Proc Natl Acad Sci U S A. 2022 Aug 30; 119: e2110105119.
Eltobgy MM, Zani A, Kenney AD, Estfanous S, Kim E, Badr A, Carafice C, Daily K, Whitham O, Pietrzak M, Webb A, Kawahara J, Eddy AC, Denz P, Lu M, Kc M, Peeples ME, Li J, Zhu J, Que J, Robinson R, Rosas Mejia O, Rayner RE, Hall-Stoodley L, Seveau S, Gavrilin MA, Zhang X, Thomas J, Kohlmeier JE, Suthar MS, Oltz E, Tedeschi A, Robledo-Avila FH, Partida-Sanchez S, Hemann EA, Abdelrazik E, Forero A, Nimjee SM, Boyaka PN, Cormet-Boyaka E, Yount JS, Amer AO. Caspase-4/11 exacerbates disease severity in SARS-CoV-2 infection by promoting inflammation and immunothrombosis. Proc Natl Acad Sci U S A. 2022 May 24; 119: e2202012119.
Koivisto K, Nieminen T, Mejias A, Capella Gonzalez C, Ye F, Mertz S, Peeples M, Ramilo O, Saxén H. Respiratory Syncytial Virus (RSV)-Specific Antibodies in Pregnant Women and Subsequent Risk of RSV Hospitalization in Young Infants. J Infect Dis. 2022 Apr 1; 225: 1189-1196.
Zeng C, Evans JP, King T, Zheng YM, Oltz EM, Whelan SPJ, Saif LJ, Peeples ME, Liu SL. SARS-CoV-2 spreads through cell-to-cell transmission. Proc Natl Acad Sci U S A. 2022 Jan 4; 119:
Mertz C, Glowinski R, Cohen SH, Mertz S, Ye F, Hall MW, Peeples ME, King T, Wang H, Leber AL, Sanchez PJ, Ramilo O, Mejias A. Severe Acute Respiratory Syndrome Coronavirus 2 RNAemia and Clinical Outcomes in Children With Coronavirus Disease 2019. J Infect Dis. 2022 Jan 18; 225: 208-213.
Xue M, Zhang Y, Wang H, Kairis EL, Lu M, Ahmad S, Attia Z, Harder O, Zhang Z, Wei J, Chen P, Gao Y, Peeples ME, Sharma A, Boyaka P, He C, Hur S, Niewiesk S, Li J. Viral RNA N6-methyladenosine modification modulates both innate and adaptive immune responses of human respiratory syncytial virus. PLoS Pathog. 2021 Dec; 17: e1010142.
Ernzen K, Trask AJ, Peeples ME, Garg V, Zhao MT. Human Stem Cell Models of SARS-CoV-2 Infection in the Cardiovascular System. Stem Cell Rev Rep. 2021 Dec; 17: 2107-2119.
Hussain SA, Rohlfing M, Resiliac J, Santoro J, Peeples ME, Garcin D, Grayson MH. Atopic Neutrophils Prevent Postviral Airway Disease. J Immunol. 2021 Nov 15; 207: 2589-2597.
Lu M, Zhang Y, Dravid P, Li A, Zeng C, Kc M, Trivedi S, Sharma H, Chaiwatpongsakorn S, Zani A, Kenney A, Cai C, Ye C, Liang X, Qiu J, Martinez-Sobrido L, Yount JS, Boyaka PN, Liu SL, Peeples ME, Kapoor A, Li J. A Methyltransferase-Defective Vesicular Stomatitis Virus-Based SARS-CoV-2 Vaccine Candidate Provides Complete Protection against SARS-CoV-2 Infection in Hamsters. J Virol. 2021 Sep 27; 95: e0059221.
Green G, Johnson SM, Costello H, Brakel K, Harder O, Oomens AG, Peeples ME, Moulton HM, Niewiesk S. CX3CR1 Is a Receptor for Human Respiratory Syncytial Virus in Cotton Rats. J Virol. 2021 Jul 26; 95: e0001021.
King T, Mejias A, Ramilo O, Peeples ME. The larger attachment glycoprotein of respiratory syncytial virus produced in primary human bronchial epithelial cultures reduces infectivity for cell lines. PLoS Pathog. 2021 Apr; 17: e1009469.
Lu M, Xue M, Wang HT, Kairis EL, Ahmad S, Wei J, Zhang Z, Liu Q, Zhang Y, Gao Y, Garcin D, Peeples ME, Sharma A, Hur S, He C, Li J. Nonsegmented Negative-Sense RNA Viruses Utilize N 6-Methyladenosine (m6A) as a Common Strategy To Evade Host Innate Immunity. J Virol. 2021 Apr 12; 95:
Cockerill GS, Angell RM, Bedernjak A, Chuckowree I, Fraser I, Gascon-Simorte J, Gilman MSA, Good JAD, Harland R, Johnson SM, Ludes-Meyers JH, Littler E, Lumley J, Lunn G, Mathews N, McLellan JS, Paradowski M, Peeples ME, Scott C, Tait D, Taylor G, Thom M, Thomas E, Villalonga Barber C, Ward SE, Watterson D, Williams G, Young P, Powell K. Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion. J Med Chem. 2021 Apr 8; 64: 3658-3676.
Lu M, Dravid P, Zhang Y, Trivedi S, Li A, Harder O, Kc M, Chaiwatpongsakorn S, Zani A, Kenney A, Zeng C, Cai C, Ye C, Liang X, Shimamura M, Liu SL, Mejias A, Ramilo O, Boyaka PN, Qiu J, Martinez-Sobrido L, Yount JS, Peeples ME, Kapoor A, Niewiesk S, Li J. A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike. Proc Natl Acad Sci U S A. 2021 Mar 23; 118:
Binjawadagi B, Ma Y, Binjawadagi R, Brakel K, Harder O, Peeples M, Li J, Niewiesk S. Mucosal Delivery of Recombinant Vesicular Stomatitis Virus Vectors Expressing Envelope Proteins of Respiratory Syncytial Virus Induces Protective Immunity in Cotton Rats. J Virol. 2021 Feb 24; 95:
Jenkins T, Wang R, Harder O, Xue M, Chen P, Corry J, Walker C, Teng M, Mejias A, Ramilo O, Niewiesk S, Li J, Peeples ME. A Novel Live Attenuated Respiratory Syncytial Virus Vaccine Candidate with Mutations in the L Protein SAM Binding Site and the G Protein Cleavage Site Is Protective in Cotton Rats and a Rhesus Macaque. J Virol. 2021 Jan 13; 95:
Martinez ME, Capella Gonzalez C, Huey D, Peeples ME, McCarty D, Niewiesk S. Immunogenicity and inflammatory properties of respiratory syncytial virus attachment G protein in cotton rats. PLoS One. 2021; 16: e0246770.
Xue M, Wang R, Harder O, Chen P, Lu M, Cai H, Li A, Liang X, Jennings R, La Perle K, Niewiesk S, Peeples ME, Li J. Stable Attenuation of Human Respiratory Syncytial Virus for Live Vaccines by Deletion and Insertion of Amino Acids in the Hinge Region between the mRNA Capping and Methyltransferase Domains of the Large Polymerase Protein. J Virol. 2020 Nov 23; 94:
Abraham RS, Marshall JM, Kuehn HS, Rueda CM, Gibbs A, Guider W, Stewart C, Rosenzweig SD, Wang H, Jean S, Peeples M, King T, Hunt WG, Honegger JR, Ramilo O, Mustillo PJ, Mejias A, Ardura MI, Shimamura M. Severe SARS-CoV-2 Disease In The Context Of A NF?B2 Loss-Of-Function Pathogenic Variant. J Allergy Clin Immunol. 2020 Sep 29;
Heinonen S, Velazquez VM, Ye F, Mertz S, Acero-Bedoya S, Smith B, Bunsow E, Garcia-Mauriño C, Oliva S, Cohen DM, Moore-Clingenpeel M, Peeples ME, Ramilo O, Mejias A. Immune profiles provide insights into respiratory syncytial virus disease severity in young children. Sci Transl Med. 2020 Apr 22; 12:
San-Juan-Vergara H, Peeples ME. Importance of Virus Characteristics in Respiratory Syncytial Virus-Induced Disease. Immunol Allergy Clin North Am. 2019 Aug; 39: 321-334.
Mejias A, Rodriguez-Fernandez R, Peeples ME, Ramilo O. Respiratory Syncytial Virus Vaccines: Are We Making Progress? Pediatr Infect Dis J. 2019 Jul 18;
Hussain SA, Mejias A, Ramilo O, Peeples ME, Grayson MH. Post-viral atopic airway disease: pathogenesis and potential avenues for intervention. Expert Rev Clin Immunol. 2019 Jan; 15: 49-58.
Chang SW, Wellmerling J, Zhang X, Rayner RE, Osman W, Mertz S, Amer AO, Peeples ME, Boyaka PN, Cormet-Boyaka E. The psychoactive substance of cannabis ?9-tetrahydrocannabinol (THC) negatively regulates CFTR in airway cells. Biochim Biophys Acta Gen Subj. 2018 Sep; 1862: 1988-1994.
Li A, Yu J, Lu M, Ma Y, Attia Z, Shan C, Xue M, Liang X, Craig K, Makadiya N, He JJ, Jennings R, Shi PY, Peeples ME, Liu SL, Boyaka PN, Li J. A Zika virus vaccine expressing premembrane-envelope-NS1 polyprotein. Nat Commun. 2018 Aug 3; 9: 3067.
Grieves JL, Yin Z, Garcia-Sastre A, Mena I, Peeples ME, Risman HP, Federman H, Sandoval MJ, Durbin RK, Durbin JE. A viral-vectored RSV vaccine induces long-lived humoral immunity in cotton rats. Vaccine. 2018 Jun 18; 36: 3842-3852.
View More Publications
Research
Lab(s)
Center for Vaccines and Immunity
The Peeples’ lab is working to understand respiratory syncytial virus (RSV), the most prominent cause of hospitalization for children. Starting with “progenitor” cells that they isolate from airways, they develop mucus-producing and cilia-waving cells. The RSV attachment glycoprotein (G) attaches RSV to ciliated cells and they have identified a virus receptor on these cells. After attaching to the cell, the viral membrane fuses with the target cell membrane, spilling the viral genome into the cell to initiate infection. They are studying both the attachment by the G protein and the fusion, driven by the RSV fusion (F) protein. F dramatically refolds to reach out to the cell membrane, grab it, and continuing to refold, pulling the two membranes together and causing them to fuse. They are working to identify the “trigger” point on the RSV F protein and what interaction initiates this refolding. In collaboration with six other labs, they are developing novel live attenuated vaccine candidates for RSV, the most common cause of hospitalization for young children in the US. They recently published their first candidate RSV vaccine, finding that a low dose of vaccine efficiently induced antibodies and was highly protective in animals. When COVID19 appeared, the Peeples’ lab shifted much of their effort toward understanding its cause, SARS-CoV-2, and how to stop it. They have made progress in understanding how the virus initiates infection of ciliated airway cells, and measured the amounts, effectiveness, and lifespan of serum antibodies to its “Spike” protein, in infected and vaccinated people. Working with colleagues at OSU and at NCH, they have developed several vaccine candidates that use the measles vaccine virus to deliver the Spike protein to the immune system. Measles vaccine is extremely safe, cheap to produce, and protects people long-term. Maybe their candidate COVID vaccines will have some of these advantages. They do induce high levels of antibodies in mice and protect hamsters from SARS-CoV-2 infection and disease. Their group is continuing to improve their vaccine candidates by modifying the Spike protein.
View My Publications
Publications
Peeples ME. Next-generation RSV vaccines avoid flipping out. Sci Transl Med. 2022 Dec 21; 14: eade9984.
Wu Q, Kumar N, Lafuse WP, Ahumada OS, Saljoughian N, Whetstone E, Zani A, Patton AK, El Refaey M, Webb A, Pietrzak M, Yu L, Kc M, Peeples ME, Ganesan LP, Yount JS, Rajaram MVS. Influenza A virus modulates ACE2 expression and SARS-CoV-2 infectivity in human cardiomyocytes. iScience. 2022 Dec 22; 25: 105701.
Taveras J, Garcia-Maurino C, Moore-Clingenpeel M, Xu Z, Mertz S, Ye F, Chen P, Cohen SH, Cohen D, Peeples ME, Ramilo O, Mejias A. Type-III Interferons, Viral Loads, Age, and Disease Severity in Young Children with Respiratory Syncytial Virus Infection. J Infect Dis. 2022 Oct 6;
Zhang Y, Zhang LS, Dai Q, Chen P, Lu M, Kairis EL, Murugaiah V, Xu J, Shukla RK, Liang X, Zou Z, Cormet-Boyaka E, Qiu J, Peeples ME, Sharma A, He C, Li J. 5-methylcytosine (m5C) RNA modification controls the innate immune response to virus infection by regulating type I interferons. Proc Natl Acad Sci U S A. 2022 Oct 18; 119: e2123338119.
Zhang Y, Lu M, Mahesh KC, Kim E, Shamseldin MM, Ye C, Dravid P, Chamblee M, Park JG, Hall JM, Trivedi S, Chaiwatpongsakorn S, Kenny AD, Murthy SS, Sharma H, Liang X, Yount JS, Kapoor A, Martinez-Sobrido L, Dubey P, Boyaka PN, Peeples ME, Li J. A highly efficacious live attenuated mumps virus-based SARS-CoV-2 vaccine candidate expressing a six-proline stabilized prefusion spike. Proc Natl Acad Sci U S A. 2022 Aug 16; 119: e2201616119.
Lu M, Chamblee M, Zhang Y, Ye C, Dravid P, Park JG, Mahesh KC, Trivedi S, Murthy S, Sharma H, Cassady C, Chaiwatpongsakorn S, Liang X, Yount JS, Boyaka PN, Peeples ME, Martinez-Sobrido L, Kapoor A, Li J. SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern. Proc Natl Acad Sci U S A. 2022 Aug 30; 119: e2110105119.
Eltobgy MM, Zani A, Kenney AD, Estfanous S, Kim E, Badr A, Carafice C, Daily K, Whitham O, Pietrzak M, Webb A, Kawahara J, Eddy AC, Denz P, Lu M, Kc M, Peeples ME, Li J, Zhu J, Que J, Robinson R, Rosas Mejia O, Rayner RE, Hall-Stoodley L, Seveau S, Gavrilin MA, Zhang X, Thomas J, Kohlmeier JE, Suthar MS, Oltz E, Tedeschi A, Robledo-Avila FH, Partida-Sanchez S, Hemann EA, Abdelrazik E, Forero A, Nimjee SM, Boyaka PN, Cormet-Boyaka E, Yount JS, Amer AO. Caspase-4/11 exacerbates disease severity in SARS-CoV-2 infection by promoting inflammation and immunothrombosis. Proc Natl Acad Sci U S A. 2022 May 24; 119: e2202012119.
Koivisto K, Nieminen T, Mejias A, Capella Gonzalez C, Ye F, Mertz S, Peeples M, Ramilo O, Saxén H. Respiratory Syncytial Virus (RSV)-Specific Antibodies in Pregnant Women and Subsequent Risk of RSV Hospitalization in Young Infants. J Infect Dis. 2022 Apr 1; 225: 1189-1196.
Zeng C, Evans JP, King T, Zheng YM, Oltz EM, Whelan SPJ, Saif LJ, Peeples ME, Liu SL. SARS-CoV-2 spreads through cell-to-cell transmission. Proc Natl Acad Sci U S A. 2022 Jan 4; 119:
Mertz C, Glowinski R, Cohen SH, Mertz S, Ye F, Hall MW, Peeples ME, King T, Wang H, Leber AL, Sanchez PJ, Ramilo O, Mejias A. Severe Acute Respiratory Syndrome Coronavirus 2 RNAemia and Clinical Outcomes in Children With Coronavirus Disease 2019. J Infect Dis. 2022 Jan 18; 225: 208-213.
Xue M, Zhang Y, Wang H, Kairis EL, Lu M, Ahmad S, Attia Z, Harder O, Zhang Z, Wei J, Chen P, Gao Y, Peeples ME, Sharma A, Boyaka P, He C, Hur S, Niewiesk S, Li J. Viral RNA N6-methyladenosine modification modulates both innate and adaptive immune responses of human respiratory syncytial virus. PLoS Pathog. 2021 Dec; 17: e1010142.
Ernzen K, Trask AJ, Peeples ME, Garg V, Zhao MT. Human Stem Cell Models of SARS-CoV-2 Infection in the Cardiovascular System. Stem Cell Rev Rep. 2021 Dec; 17: 2107-2119.
Hussain SA, Rohlfing M, Resiliac J, Santoro J, Peeples ME, Garcin D, Grayson MH. Atopic Neutrophils Prevent Postviral Airway Disease. J Immunol. 2021 Nov 15; 207: 2589-2597.
Lu M, Zhang Y, Dravid P, Li A, Zeng C, Kc M, Trivedi S, Sharma H, Chaiwatpongsakorn S, Zani A, Kenney A, Cai C, Ye C, Liang X, Qiu J, Martinez-Sobrido L, Yount JS, Boyaka PN, Liu SL, Peeples ME, Kapoor A, Li J. A Methyltransferase-Defective Vesicular Stomatitis Virus-Based SARS-CoV-2 Vaccine Candidate Provides Complete Protection against SARS-CoV-2 Infection in Hamsters. J Virol. 2021 Sep 27; 95: e0059221.
Green G, Johnson SM, Costello H, Brakel K, Harder O, Oomens AG, Peeples ME, Moulton HM, Niewiesk S. CX3CR1 Is a Receptor for Human Respiratory Syncytial Virus in Cotton Rats. J Virol. 2021 Jul 26; 95: e0001021.
King T, Mejias A, Ramilo O, Peeples ME. The larger attachment glycoprotein of respiratory syncytial virus produced in primary human bronchial epithelial cultures reduces infectivity for cell lines. PLoS Pathog. 2021 Apr; 17: e1009469.
Lu M, Xue M, Wang HT, Kairis EL, Ahmad S, Wei J, Zhang Z, Liu Q, Zhang Y, Gao Y, Garcin D, Peeples ME, Sharma A, Hur S, He C, Li J. Nonsegmented Negative-Sense RNA Viruses Utilize N 6-Methyladenosine (m6A) as a Common Strategy To Evade Host Innate Immunity. J Virol. 2021 Apr 12; 95:
Cockerill GS, Angell RM, Bedernjak A, Chuckowree I, Fraser I, Gascon-Simorte J, Gilman MSA, Good JAD, Harland R, Johnson SM, Ludes-Meyers JH, Littler E, Lumley J, Lunn G, Mathews N, McLellan JS, Paradowski M, Peeples ME, Scott C, Tait D, Taylor G, Thom M, Thomas E, Villalonga Barber C, Ward SE, Watterson D, Williams G, Young P, Powell K. Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion. J Med Chem. 2021 Apr 8; 64: 3658-3676.
Lu M, Dravid P, Zhang Y, Trivedi S, Li A, Harder O, Kc M, Chaiwatpongsakorn S, Zani A, Kenney A, Zeng C, Cai C, Ye C, Liang X, Shimamura M, Liu SL, Mejias A, Ramilo O, Boyaka PN, Qiu J, Martinez-Sobrido L, Yount JS, Peeples ME, Kapoor A, Niewiesk S, Li J. A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike. Proc Natl Acad Sci U S A. 2021 Mar 23; 118:
Binjawadagi B, Ma Y, Binjawadagi R, Brakel K, Harder O, Peeples M, Li J, Niewiesk S. Mucosal Delivery of Recombinant Vesicular Stomatitis Virus Vectors Expressing Envelope Proteins of Respiratory Syncytial Virus Induces Protective Immunity in Cotton Rats. J Virol. 2021 Feb 24; 95:
Jenkins T, Wang R, Harder O, Xue M, Chen P, Corry J, Walker C, Teng M, Mejias A, Ramilo O, Niewiesk S, Li J, Peeples ME. A Novel Live Attenuated Respiratory Syncytial Virus Vaccine Candidate with Mutations in the L Protein SAM Binding Site and the G Protein Cleavage Site Is Protective in Cotton Rats and a Rhesus Macaque. J Virol. 2021 Jan 13; 95:
Martinez ME, Capella Gonzalez C, Huey D, Peeples ME, McCarty D, Niewiesk S. Immunogenicity and inflammatory properties of respiratory syncytial virus attachment G protein in cotton rats. PLoS One. 2021; 16: e0246770.
Xue M, Wang R, Harder O, Chen P, Lu M, Cai H, Li A, Liang X, Jennings R, La Perle K, Niewiesk S, Peeples ME, Li J. Stable Attenuation of Human Respiratory Syncytial Virus for Live Vaccines by Deletion and Insertion of Amino Acids in the Hinge Region between the mRNA Capping and Methyltransferase Domains of the Large Polymerase Protein. J Virol. 2020 Nov 23; 94:
Abraham RS, Marshall JM, Kuehn HS, Rueda CM, Gibbs A, Guider W, Stewart C, Rosenzweig SD, Wang H, Jean S, Peeples M, King T, Hunt WG, Honegger JR, Ramilo O, Mustillo PJ, Mejias A, Ardura MI, Shimamura M. Severe SARS-CoV-2 Disease In The Context Of A NF?B2 Loss-Of-Function Pathogenic Variant. J Allergy Clin Immunol. 2020 Sep 29;
Heinonen S, Velazquez VM, Ye F, Mertz S, Acero-Bedoya S, Smith B, Bunsow E, Garcia-Mauriño C, Oliva S, Cohen DM, Moore-Clingenpeel M, Peeples ME, Ramilo O, Mejias A. Immune profiles provide insights into respiratory syncytial virus disease severity in young children. Sci Transl Med. 2020 Apr 22; 12:
San-Juan-Vergara H, Peeples ME. Importance of Virus Characteristics in Respiratory Syncytial Virus-Induced Disease. Immunol Allergy Clin North Am. 2019 Aug; 39: 321-334.
Mejias A, Rodriguez-Fernandez R, Peeples ME, Ramilo O. Respiratory Syncytial Virus Vaccines: Are We Making Progress? Pediatr Infect Dis J. 2019 Jul 18;
Hussain SA, Mejias A, Ramilo O, Peeples ME, Grayson MH. Post-viral atopic airway disease: pathogenesis and potential avenues for intervention. Expert Rev Clin Immunol. 2019 Jan; 15: 49-58.
Chang SW, Wellmerling J, Zhang X, Rayner RE, Osman W, Mertz S, Amer AO, Peeples ME, Boyaka PN, Cormet-Boyaka E. The psychoactive substance of cannabis ?9-tetrahydrocannabinol (THC) negatively regulates CFTR in airway cells. Biochim Biophys Acta Gen Subj. 2018 Sep; 1862: 1988-1994.
Li A, Yu J, Lu M, Ma Y, Attia Z, Shan C, Xue M, Liang X, Craig K, Makadiya N, He JJ, Jennings R, Shi PY, Peeples ME, Liu SL, Boyaka PN, Li J. A Zika virus vaccine expressing premembrane-envelope-NS1 polyprotein. Nat Commun. 2018 Aug 3; 9: 3067.
Grieves JL, Yin Z, Garcia-Sastre A, Mena I, Peeples ME, Risman HP, Federman H, Sandoval MJ, Durbin RK, Durbin JE. A viral-vectored RSV vaccine induces long-lived humoral immunity in cotton rats. Vaccine. 2018 Jun 18; 36: 3842-3852.
View More Publications
Lab(s)
Center for Vaccines and Immunity
The Peeples’ lab is working to understand respiratory syncytial virus (RSV), the most prominent cause of hospitalization for children. Starting with “progenitor” cells that they isolate from airways, they develop mucus-producing and cilia-waving cells. The RSV attachment glycoprotein (G) attaches RSV to ciliated cells and they have identified a virus receptor on these cells. After attaching to the cell, the viral membrane fuses with the target cell membrane, spilling the viral genome into the cell to initiate infection. They are studying both the attachment by the G protein and the fusion, driven by the RSV fusion (F) protein. F dramatically refolds to reach out to the cell membrane, grab it, and continuing to refold, pulling the two membranes together and causing them to fuse. They are working to identify the “trigger” point on the RSV F protein and what interaction initiates this refolding. In collaboration with six other labs, they are developing novel live attenuated vaccine candidates for RSV, the most common cause of hospitalization for young children in the US. They recently published their first candidate RSV vaccine, finding that a low dose of vaccine efficiently induced antibodies and was highly protective in animals. When COVID19 appeared, the Peeples’ lab shifted much of their effort toward understanding its cause, SARS-CoV-2, and how to stop it. They have made progress in understanding how the virus initiates infection of ciliated airway cells, and measured the amounts, effectiveness, and lifespan of serum antibodies to its “Spike” protein, in infected and vaccinated people. Working with colleagues at OSU and at NCH, they have developed several vaccine candidates that use the measles vaccine virus to deliver the Spike protein to the immune system. Measles vaccine is extremely safe, cheap to produce, and protects people long-term. Maybe their candidate COVID vaccines will have some of these advantages. They do induce high levels of antibodies in mice and protect hamsters from SARS-CoV-2 infection and disease. Their group is continuing to improve their vaccine candidates by modifying the Spike protein.
View My Publications
Publications
Peeples ME. Next-generation RSV vaccines avoid flipping out. Sci Transl Med. 2022 Dec 21; 14: eade9984.
Wu Q, Kumar N, Lafuse WP, Ahumada OS, Saljoughian N, Whetstone E, Zani A, Patton AK, El Refaey M, Webb A, Pietrzak M, Yu L, Kc M, Peeples ME, Ganesan LP, Yount JS, Rajaram MVS. Influenza A virus modulates ACE2 expression and SARS-CoV-2 infectivity in human cardiomyocytes. iScience. 2022 Dec 22; 25: 105701.
Taveras J, Garcia-Maurino C, Moore-Clingenpeel M, Xu Z, Mertz S, Ye F, Chen P, Cohen SH, Cohen D, Peeples ME, Ramilo O, Mejias A. Type-III Interferons, Viral Loads, Age, and Disease Severity in Young Children with Respiratory Syncytial Virus Infection. J Infect Dis. 2022 Oct 6;
Zhang Y, Zhang LS, Dai Q, Chen P, Lu M, Kairis EL, Murugaiah V, Xu J, Shukla RK, Liang X, Zou Z, Cormet-Boyaka E, Qiu J, Peeples ME, Sharma A, He C, Li J. 5-methylcytosine (m5C) RNA modification controls the innate immune response to virus infection by regulating type I interferons. Proc Natl Acad Sci U S A. 2022 Oct 18; 119: e2123338119.
Zhang Y, Lu M, Mahesh KC, Kim E, Shamseldin MM, Ye C, Dravid P, Chamblee M, Park JG, Hall JM, Trivedi S, Chaiwatpongsakorn S, Kenny AD, Murthy SS, Sharma H, Liang X, Yount JS, Kapoor A, Martinez-Sobrido L, Dubey P, Boyaka PN, Peeples ME, Li J. A highly efficacious live attenuated mumps virus-based SARS-CoV-2 vaccine candidate expressing a six-proline stabilized prefusion spike. Proc Natl Acad Sci U S A. 2022 Aug 16; 119: e2201616119.
Lu M, Chamblee M, Zhang Y, Ye C, Dravid P, Park JG, Mahesh KC, Trivedi S, Murthy S, Sharma H, Cassady C, Chaiwatpongsakorn S, Liang X, Yount JS, Boyaka PN, Peeples ME, Martinez-Sobrido L, Kapoor A, Li J. SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern. Proc Natl Acad Sci U S A. 2022 Aug 30; 119: e2110105119.
Eltobgy MM, Zani A, Kenney AD, Estfanous S, Kim E, Badr A, Carafice C, Daily K, Whitham O, Pietrzak M, Webb A, Kawahara J, Eddy AC, Denz P, Lu M, Kc M, Peeples ME, Li J, Zhu J, Que J, Robinson R, Rosas Mejia O, Rayner RE, Hall-Stoodley L, Seveau S, Gavrilin MA, Zhang X, Thomas J, Kohlmeier JE, Suthar MS, Oltz E, Tedeschi A, Robledo-Avila FH, Partida-Sanchez S, Hemann EA, Abdelrazik E, Forero A, Nimjee SM, Boyaka PN, Cormet-Boyaka E, Yount JS, Amer AO. Caspase-4/11 exacerbates disease severity in SARS-CoV-2 infection by promoting inflammation and immunothrombosis. Proc Natl Acad Sci U S A. 2022 May 24; 119: e2202012119.
Koivisto K, Nieminen T, Mejias A, Capella Gonzalez C, Ye F, Mertz S, Peeples M, Ramilo O, Saxén H. Respiratory Syncytial Virus (RSV)-Specific Antibodies in Pregnant Women and Subsequent Risk of RSV Hospitalization in Young Infants. J Infect Dis. 2022 Apr 1; 225: 1189-1196.
Zeng C, Evans JP, King T, Zheng YM, Oltz EM, Whelan SPJ, Saif LJ, Peeples ME, Liu SL. SARS-CoV-2 spreads through cell-to-cell transmission. Proc Natl Acad Sci U S A. 2022 Jan 4; 119:
Mertz C, Glowinski R, Cohen SH, Mertz S, Ye F, Hall MW, Peeples ME, King T, Wang H, Leber AL, Sanchez PJ, Ramilo O, Mejias A. Severe Acute Respiratory Syndrome Coronavirus 2 RNAemia and Clinical Outcomes in Children With Coronavirus Disease 2019. J Infect Dis. 2022 Jan 18; 225: 208-213.
Xue M, Zhang Y, Wang H, Kairis EL, Lu M, Ahmad S, Attia Z, Harder O, Zhang Z, Wei J, Chen P, Gao Y, Peeples ME, Sharma A, Boyaka P, He C, Hur S, Niewiesk S, Li J. Viral RNA N6-methyladenosine modification modulates both innate and adaptive immune responses of human respiratory syncytial virus. PLoS Pathog. 2021 Dec; 17: e1010142.
Ernzen K, Trask AJ, Peeples ME, Garg V, Zhao MT. Human Stem Cell Models of SARS-CoV-2 Infection in the Cardiovascular System. Stem Cell Rev Rep. 2021 Dec; 17: 2107-2119.
Hussain SA, Rohlfing M, Resiliac J, Santoro J, Peeples ME, Garcin D, Grayson MH. Atopic Neutrophils Prevent Postviral Airway Disease. J Immunol. 2021 Nov 15; 207: 2589-2597.
Lu M, Zhang Y, Dravid P, Li A, Zeng C, Kc M, Trivedi S, Sharma H, Chaiwatpongsakorn S, Zani A, Kenney A, Cai C, Ye C, Liang X, Qiu J, Martinez-Sobrido L, Yount JS, Boyaka PN, Liu SL, Peeples ME, Kapoor A, Li J. A Methyltransferase-Defective Vesicular Stomatitis Virus-Based SARS-CoV-2 Vaccine Candidate Provides Complete Protection against SARS-CoV-2 Infection in Hamsters. J Virol. 2021 Sep 27; 95: e0059221.
Green G, Johnson SM, Costello H, Brakel K, Harder O, Oomens AG, Peeples ME, Moulton HM, Niewiesk S. CX3CR1 Is a Receptor for Human Respiratory Syncytial Virus in Cotton Rats. J Virol. 2021 Jul 26; 95: e0001021.
King T, Mejias A, Ramilo O, Peeples ME. The larger attachment glycoprotein of respiratory syncytial virus produced in primary human bronchial epithelial cultures reduces infectivity for cell lines. PLoS Pathog. 2021 Apr; 17: e1009469.
Lu M, Xue M, Wang HT, Kairis EL, Ahmad S, Wei J, Zhang Z, Liu Q, Zhang Y, Gao Y, Garcin D, Peeples ME, Sharma A, Hur S, He C, Li J. Nonsegmented Negative-Sense RNA Viruses Utilize N 6-Methyladenosine (m6A) as a Common Strategy To Evade Host Innate Immunity. J Virol. 2021 Apr 12; 95:
Cockerill GS, Angell RM, Bedernjak A, Chuckowree I, Fraser I, Gascon-Simorte J, Gilman MSA, Good JAD, Harland R, Johnson SM, Ludes-Meyers JH, Littler E, Lumley J, Lunn G, Mathews N, McLellan JS, Paradowski M, Peeples ME, Scott C, Tait D, Taylor G, Thom M, Thomas E, Villalonga Barber C, Ward SE, Watterson D, Williams G, Young P, Powell K. Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion. J Med Chem. 2021 Apr 8; 64: 3658-3676.
Lu M, Dravid P, Zhang Y, Trivedi S, Li A, Harder O, Kc M, Chaiwatpongsakorn S, Zani A, Kenney A, Zeng C, Cai C, Ye C, Liang X, Shimamura M, Liu SL, Mejias A, Ramilo O, Boyaka PN, Qiu J, Martinez-Sobrido L, Yount JS, Peeples ME, Kapoor A, Niewiesk S, Li J. A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike. Proc Natl Acad Sci U S A. 2021 Mar 23; 118:
Binjawadagi B, Ma Y, Binjawadagi R, Brakel K, Harder O, Peeples M, Li J, Niewiesk S. Mucosal Delivery of Recombinant Vesicular Stomatitis Virus Vectors Expressing Envelope Proteins of Respiratory Syncytial Virus Induces Protective Immunity in Cotton Rats. J Virol. 2021 Feb 24; 95:
Jenkins T, Wang R, Harder O, Xue M, Chen P, Corry J, Walker C, Teng M, Mejias A, Ramilo O, Niewiesk S, Li J, Peeples ME. A Novel Live Attenuated Respiratory Syncytial Virus Vaccine Candidate with Mutations in the L Protein SAM Binding Site and the G Protein Cleavage Site Is Protective in Cotton Rats and a Rhesus Macaque. J Virol. 2021 Jan 13; 95:
Martinez ME, Capella Gonzalez C, Huey D, Peeples ME, McCarty D, Niewiesk S. Immunogenicity and inflammatory properties of respiratory syncytial virus attachment G protein in cotton rats. PLoS One. 2021; 16: e0246770.
Xue M, Wang R, Harder O, Chen P, Lu M, Cai H, Li A, Liang X, Jennings R, La Perle K, Niewiesk S, Peeples ME, Li J. Stable Attenuation of Human Respiratory Syncytial Virus for Live Vaccines by Deletion and Insertion of Amino Acids in the Hinge Region between the mRNA Capping and Methyltransferase Domains of the Large Polymerase Protein. J Virol. 2020 Nov 23; 94:
Abraham RS, Marshall JM, Kuehn HS, Rueda CM, Gibbs A, Guider W, Stewart C, Rosenzweig SD, Wang H, Jean S, Peeples M, King T, Hunt WG, Honegger JR, Ramilo O, Mustillo PJ, Mejias A, Ardura MI, Shimamura M. Severe SARS-CoV-2 Disease In The Context Of A NF?B2 Loss-Of-Function Pathogenic Variant. J Allergy Clin Immunol. 2020 Sep 29;
Heinonen S, Velazquez VM, Ye F, Mertz S, Acero-Bedoya S, Smith B, Bunsow E, Garcia-Mauriño C, Oliva S, Cohen DM, Moore-Clingenpeel M, Peeples ME, Ramilo O, Mejias A. Immune profiles provide insights into respiratory syncytial virus disease severity in young children. Sci Transl Med. 2020 Apr 22; 12:
San-Juan-Vergara H, Peeples ME. Importance of Virus Characteristics in Respiratory Syncytial Virus-Induced Disease. Immunol Allergy Clin North Am. 2019 Aug; 39: 321-334.
Mejias A, Rodriguez-Fernandez R, Peeples ME, Ramilo O. Respiratory Syncytial Virus Vaccines: Are We Making Progress? Pediatr Infect Dis J. 2019 Jul 18;
Hussain SA, Mejias A, Ramilo O, Peeples ME, Grayson MH. Post-viral atopic airway disease: pathogenesis and potential avenues for intervention. Expert Rev Clin Immunol. 2019 Jan; 15: 49-58.
Chang SW, Wellmerling J, Zhang X, Rayner RE, Osman W, Mertz S, Amer AO, Peeples ME, Boyaka PN, Cormet-Boyaka E. The psychoactive substance of cannabis ?9-tetrahydrocannabinol (THC) negatively regulates CFTR in airway cells. Biochim Biophys Acta Gen Subj. 2018 Sep; 1862: 1988-1994.
Li A, Yu J, Lu M, Ma Y, Attia Z, Shan C, Xue M, Liang X, Craig K, Makadiya N, He JJ, Jennings R, Shi PY, Peeples ME, Liu SL, Boyaka PN, Li J. A Zika virus vaccine expressing premembrane-envelope-NS1 polyprotein. Nat Commun. 2018 Aug 3; 9: 3067.
Grieves JL, Yin Z, Garcia-Sastre A, Mena I, Peeples ME, Risman HP, Federman H, Sandoval MJ, Durbin RK, Durbin JE. A viral-vectored RSV vaccine induces long-lived humoral immunity in cotton rats. Vaccine. 2018 Jun 18; 36: 3842-3852.
View More Publications
Lab(s)
Center for Vaccines and Immunity
The Peeples’ lab is working to understand respiratory syncytial virus (RSV), the most prominent cause of hospitalization for children. Starting with “progenitor” cells that they isolate from airways, they develop mucus-producing and cilia-waving cells. The RSV attachment glycoprotein (G) attaches RSV to ciliated cells and they have identified a virus receptor on these cells. After attaching to the cell, the viral membrane fuses with the target cell membrane, spilling the viral genome into the cell to initiate infection. They are studying both the attachment by the G protein and the fusion, driven by the RSV fusion (F) protein. F dramatically refolds to reach out to the cell membrane, grab it, and continuing to refold, pulling the two membranes together and causing them to fuse. They are working to identify the “trigger” point on the RSV F protein and what interaction initiates this refolding. In collaboration with six other labs, they are developing novel live attenuated vaccine candidates for RSV, the most common cause of hospitalization for young children in the US. They recently published their first candidate RSV vaccine, finding that a low dose of vaccine efficiently induced antibodies and was highly protective in animals.
Lab(s)
Center for Vaccines and Immunity
- Center for Vaccines and Immunity
When COVID19 appeared, the Peeples’ lab shifted much of their effort toward understanding its cause, SARS-CoV-2, and how to stop it. They have made progress in understanding how the virus initiates infection of ciliated airway cells, and measured the amounts, effectiveness, and lifespan of serum antibodies to its “Spike” protein, in infected and vaccinated people. Working with colleagues at OSU and at NCH, they have developed several vaccine candidates that use the measles vaccine virus to deliver the Spike protein to the immune system. Measles vaccine is extremely safe, cheap to produce, and protects people long-term. Maybe their candidate COVID vaccines will have some of these advantages. They do induce high levels of antibodies in mice and protect hamsters from SARS-CoV-2 infection and disease. Their group is continuing to improve their vaccine candidates by modifying the Spike protein.
View My Publications
Peeples ME. Next-generation RSV vaccines avoid flipping out. Sci Transl Med. 2022 Dec 21; 14: eade9984. Wu Q, Kumar N, Lafuse WP, Ahumada OS, Saljoughian N, Whetstone E, Zani A, Patton AK, El Refaey M, Webb A, Pietrzak M, Yu L, Kc M, Peeples ME, Ganesan LP, Yount JS, Rajaram MVS. Influenza A virus modulates ACE2 expression and SARS-CoV-2 infectivity in human cardiomyocytes. iScience. 2022 Dec 22; 25: 105701. Taveras J, Garcia-Maurino C, Moore-Clingenpeel M, Xu Z, Mertz S, Ye F, Chen P, Cohen SH, Cohen D, Peeples ME, Ramilo O, Mejias A. Type-III Interferons, Viral Loads, Age, and Disease Severity in Young Children with Respiratory Syncytial Virus Infection. J Infect Dis. 2022 Oct 6; Zhang Y, Zhang LS, Dai Q, Chen P, Lu M, Kairis EL, Murugaiah V, Xu J, Shukla RK, Liang X, Zou Z, Cormet-Boyaka E, Qiu J, Peeples ME, Sharma A, He C, Li J. 5-methylcytosine (m5C) RNA modification controls the innate immune response to virus infection by regulating type I interferons. Proc Natl Acad Sci U S A. 2022 Oct 18; 119: e2123338119. Zhang Y, Lu M, Mahesh KC, Kim E, Shamseldin MM, Ye C, Dravid P, Chamblee M, Park JG, Hall JM, Trivedi S, Chaiwatpongsakorn S, Kenny AD, Murthy SS, Sharma H, Liang X, Yount JS, Kapoor A, Martinez-Sobrido L, Dubey P, Boyaka PN, Peeples ME, Li J. A highly efficacious live attenuated mumps virus-based SARS-CoV-2 vaccine candidate expressing a six-proline stabilized prefusion spike. Proc Natl Acad Sci U S A. 2022 Aug 16; 119: e2201616119. Lu M, Chamblee M, Zhang Y, Ye C, Dravid P, Park JG, Mahesh KC, Trivedi S, Murthy S, Sharma H, Cassady C, Chaiwatpongsakorn S, Liang X, Yount JS, Boyaka PN, Peeples ME, Martinez-Sobrido L, Kapoor A, Li J. SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern. Proc Natl Acad Sci U S A. 2022 Aug 30; 119: e2110105119. Eltobgy MM, Zani A, Kenney AD, Estfanous S, Kim E, Badr A, Carafice C, Daily K, Whitham O, Pietrzak M, Webb A, Kawahara J, Eddy AC, Denz P, Lu M, Kc M, Peeples ME, Li J, Zhu J, Que J, Robinson R, Rosas Mejia O, Rayner RE, Hall-Stoodley L, Seveau S, Gavrilin MA, Zhang X, Thomas J, Kohlmeier JE, Suthar MS, Oltz E, Tedeschi A, Robledo-Avila FH, Partida-Sanchez S, Hemann EA, Abdelrazik E, Forero A, Nimjee SM, Boyaka PN, Cormet-Boyaka E, Yount JS, Amer AO. Caspase-4/11 exacerbates disease severity in SARS-CoV-2 infection by promoting inflammation and immunothrombosis. Proc Natl Acad Sci U S A. 2022 May 24; 119: e2202012119. Koivisto K, Nieminen T, Mejias A, Capella Gonzalez C, Ye F, Mertz S, Peeples M, Ramilo O, Saxén H. Respiratory Syncytial Virus (RSV)-Specific Antibodies in Pregnant Women and Subsequent Risk of RSV Hospitalization in Young Infants. J Infect Dis. 2022 Apr 1; 225: 1189-1196. Zeng C, Evans JP, King T, Zheng YM, Oltz EM, Whelan SPJ, Saif LJ, Peeples ME, Liu SL. SARS-CoV-2 spreads through cell-to-cell transmission. Proc Natl Acad Sci U S A. 2022 Jan 4; 119: Mertz C, Glowinski R, Cohen SH, Mertz S, Ye F, Hall MW, Peeples ME, King T, Wang H, Leber AL, Sanchez PJ, Ramilo O, Mejias A. Severe Acute Respiratory Syndrome Coronavirus 2 RNAemia and Clinical Outcomes in Children With Coronavirus Disease 2019. J Infect Dis. 2022 Jan 18; 225: 208-213. Xue M, Zhang Y, Wang H, Kairis EL, Lu M, Ahmad S, Attia Z, Harder O, Zhang Z, Wei J, Chen P, Gao Y, Peeples ME, Sharma A, Boyaka P, He C, Hur S, Niewiesk S, Li J. Viral RNA N6-methyladenosine modification modulates both innate and adaptive immune responses of human respiratory syncytial virus. PLoS Pathog. 2021 Dec; 17: e1010142. Ernzen K, Trask AJ, Peeples ME, Garg V, Zhao MT. Human Stem Cell Models of SARS-CoV-2 Infection in the Cardiovascular System. Stem Cell Rev Rep. 2021 Dec; 17: 2107-2119. Hussain SA, Rohlfing M, Resiliac J, Santoro J, Peeples ME, Garcin D, Grayson MH. Atopic Neutrophils Prevent Postviral Airway Disease. J Immunol. 2021 Nov 15; 207: 2589-2597. Lu M, Zhang Y, Dravid P, Li A, Zeng C, Kc M, Trivedi S, Sharma H, Chaiwatpongsakorn S, Zani A, Kenney A, Cai C, Ye C, Liang X, Qiu J, Martinez-Sobrido L, Yount JS, Boyaka PN, Liu SL, Peeples ME, Kapoor A, Li J. A Methyltransferase-Defective Vesicular Stomatitis Virus-Based SARS-CoV-2 Vaccine Candidate Provides Complete Protection against SARS-CoV-2 Infection in Hamsters. J Virol. 2021 Sep 27; 95: e0059221. Green G, Johnson SM, Costello H, Brakel K, Harder O, Oomens AG, Peeples ME, Moulton HM, Niewiesk S. CX3CR1 Is a Receptor for Human Respiratory Syncytial Virus in Cotton Rats. J Virol. 2021 Jul 26; 95: e0001021. King T, Mejias A, Ramilo O, Peeples ME. The larger attachment glycoprotein of respiratory syncytial virus produced in primary human bronchial epithelial cultures reduces infectivity for cell lines. PLoS Pathog. 2021 Apr; 17: e1009469. Lu M, Xue M, Wang HT, Kairis EL, Ahmad S, Wei J, Zhang Z, Liu Q, Zhang Y, Gao Y, Garcin D, Peeples ME, Sharma A, Hur S, He C, Li J. Nonsegmented Negative-Sense RNA Viruses Utilize N 6-Methyladenosine (m6A) as a Common Strategy To Evade Host Innate Immunity. J Virol. 2021 Apr 12; 95: Cockerill GS, Angell RM, Bedernjak A, Chuckowree I, Fraser I, Gascon-Simorte J, Gilman MSA, Good JAD, Harland R, Johnson SM, Ludes-Meyers JH, Littler E, Lumley J, Lunn G, Mathews N, McLellan JS, Paradowski M, Peeples ME, Scott C, Tait D, Taylor G, Thom M, Thomas E, Villalonga Barber C, Ward SE, Watterson D, Williams G, Young P, Powell K. Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion. J Med Chem. 2021 Apr 8; 64: 3658-3676. Lu M, Dravid P, Zhang Y, Trivedi S, Li A, Harder O, Kc M, Chaiwatpongsakorn S, Zani A, Kenney A, Zeng C, Cai C, Ye C, Liang X, Shimamura M, Liu SL, Mejias A, Ramilo O, Boyaka PN, Qiu J, Martinez-Sobrido L, Yount JS, Peeples ME, Kapoor A, Niewiesk S, Li J. A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike. Proc Natl Acad Sci U S A. 2021 Mar 23; 118: Binjawadagi B, Ma Y, Binjawadagi R, Brakel K, Harder O, Peeples M, Li J, Niewiesk S. Mucosal Delivery of Recombinant Vesicular Stomatitis Virus Vectors Expressing Envelope Proteins of Respiratory Syncytial Virus Induces Protective Immunity in Cotton Rats. J Virol. 2021 Feb 24; 95: Jenkins T, Wang R, Harder O, Xue M, Chen P, Corry J, Walker C, Teng M, Mejias A, Ramilo O, Niewiesk S, Li J, Peeples ME. A Novel Live Attenuated Respiratory Syncytial Virus Vaccine Candidate with Mutations in the L Protein SAM Binding Site and the G Protein Cleavage Site Is Protective in Cotton Rats and a Rhesus Macaque. J Virol. 2021 Jan 13; 95: Martinez ME, Capella Gonzalez C, Huey D, Peeples ME, McCarty D, Niewiesk S. Immunogenicity and inflammatory properties of respiratory syncytial virus attachment G protein in cotton rats. PLoS One. 2021; 16: e0246770. Xue M, Wang R, Harder O, Chen P, Lu M, Cai H, Li A, Liang X, Jennings R, La Perle K, Niewiesk S, Peeples ME, Li J. Stable Attenuation of Human Respiratory Syncytial Virus for Live Vaccines by Deletion and Insertion of Amino Acids in the Hinge Region between the mRNA Capping and Methyltransferase Domains of the Large Polymerase Protein. J Virol. 2020 Nov 23; 94: Abraham RS, Marshall JM, Kuehn HS, Rueda CM, Gibbs A, Guider W, Stewart C, Rosenzweig SD, Wang H, Jean S, Peeples M, King T, Hunt WG, Honegger JR, Ramilo O, Mustillo PJ, Mejias A, Ardura MI, Shimamura M. Severe SARS-CoV-2 Disease In The Context Of A NF?B2 Loss-Of-Function Pathogenic Variant. J Allergy Clin Immunol. 2020 Sep 29; Heinonen S, Velazquez VM, Ye F, Mertz S, Acero-Bedoya S, Smith B, Bunsow E, Garcia-Mauriño C, Oliva S, Cohen DM, Moore-Clingenpeel M, Peeples ME, Ramilo O, Mejias A. Immune profiles provide insights into respiratory syncytial virus disease severity in young children. Sci Transl Med. 2020 Apr 22; 12: San-Juan-Vergara H, Peeples ME. Importance of Virus Characteristics in Respiratory Syncytial Virus-Induced Disease. Immunol Allergy Clin North Am. 2019 Aug; 39: 321-334. Mejias A, Rodriguez-Fernandez R, Peeples ME, Ramilo O. Respiratory Syncytial Virus Vaccines: Are We Making Progress? Pediatr Infect Dis J. 2019 Jul 18; Hussain SA, Mejias A, Ramilo O, Peeples ME, Grayson MH. Post-viral atopic airway disease: pathogenesis and potential avenues for intervention. Expert Rev Clin Immunol. 2019 Jan; 15: 49-58. Chang SW, Wellmerling J, Zhang X, Rayner RE, Osman W, Mertz S, Amer AO, Peeples ME, Boyaka PN, Cormet-Boyaka E. The psychoactive substance of cannabis ?9-tetrahydrocannabinol (THC) negatively regulates CFTR in airway cells. Biochim Biophys Acta Gen Subj. 2018 Sep; 1862: 1988-1994. Li A, Yu J, Lu M, Ma Y, Attia Z, Shan C, Xue M, Liang X, Craig K, Makadiya N, He JJ, Jennings R, Shi PY, Peeples ME, Liu SL, Boyaka PN, Li J. A Zika virus vaccine expressing premembrane-envelope-NS1 polyprotein. Nat Commun. 2018 Aug 3; 9: 3067. Grieves JL, Yin Z, Garcia-Sastre A, Mena I, Peeples ME, Risman HP, Federman H, Sandoval MJ, Durbin RK, Durbin JE. A viral-vectored RSV vaccine induces long-lived humoral immunity in cotton rats. Vaccine. 2018 Jun 18; 36: 3842-3852.
View More Publications
- Peeples ME. Next-generation RSV vaccines avoid flipping out. Sci Transl Med. 2022 Dec 21; 14: eade9984.
- Wu Q, Kumar N, Lafuse WP, Ahumada OS, Saljoughian N, Whetstone E, Zani A, Patton AK, El Refaey M, Webb A, Pietrzak M, Yu L, Kc M, Peeples ME, Ganesan LP, Yount JS, Rajaram MVS. Influenza A virus modulates ACE2 expression and SARS-CoV-2 infectivity in human cardiomyocytes. iScience. 2022 Dec 22; 25: 105701.
- Taveras J, Garcia-Maurino C, Moore-Clingenpeel M, Xu Z, Mertz S, Ye F, Chen P, Cohen SH, Cohen D, Peeples ME, Ramilo O, Mejias A. Type-III Interferons, Viral Loads, Age, and Disease Severity in Young Children with Respiratory Syncytial Virus Infection. J Infect Dis. 2022 Oct 6;
- Zhang Y, Zhang LS, Dai Q, Chen P, Lu M, Kairis EL, Murugaiah V, Xu J, Shukla RK, Liang X, Zou Z, Cormet-Boyaka E, Qiu J, Peeples ME, Sharma A, He C, Li J. 5-methylcytosine (m5C) RNA modification controls the innate immune response to virus infection by regulating type I interferons. Proc Natl Acad Sci U S A. 2022 Oct 18; 119: e2123338119.
- Zhang Y, Lu M, Mahesh KC, Kim E, Shamseldin MM, Ye C, Dravid P, Chamblee M, Park JG, Hall JM, Trivedi S, Chaiwatpongsakorn S, Kenny AD, Murthy SS, Sharma H, Liang X, Yount JS, Kapoor A, Martinez-Sobrido L, Dubey P, Boyaka PN, Peeples ME, Li J. A highly efficacious live attenuated mumps virus-based SARS-CoV-2 vaccine candidate expressing a six-proline stabilized prefusion spike. Proc Natl Acad Sci U S A. 2022 Aug 16; 119: e2201616119.
- Lu M, Chamblee M, Zhang Y, Ye C, Dravid P, Park JG, Mahesh KC, Trivedi S, Murthy S, Sharma H, Cassady C, Chaiwatpongsakorn S, Liang X, Yount JS, Boyaka PN, Peeples ME, Martinez-Sobrido L, Kapoor A, Li J. SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern. Proc Natl Acad Sci U S A. 2022 Aug 30; 119: e2110105119.
- Eltobgy MM, Zani A, Kenney AD, Estfanous S, Kim E, Badr A, Carafice C, Daily K, Whitham O, Pietrzak M, Webb A, Kawahara J, Eddy AC, Denz P, Lu M, Kc M, Peeples ME, Li J, Zhu J, Que J, Robinson R, Rosas Mejia O, Rayner RE, Hall-Stoodley L, Seveau S, Gavrilin MA, Zhang X, Thomas J, Kohlmeier JE, Suthar MS, Oltz E, Tedeschi A, Robledo-Avila FH, Partida-Sanchez S, Hemann EA, Abdelrazik E, Forero A, Nimjee SM, Boyaka PN, Cormet-Boyaka E, Yount JS, Amer AO. Caspase-4/11 exacerbates disease severity in SARS-CoV-2 infection by promoting inflammation and immunothrombosis. Proc Natl Acad Sci U S A. 2022 May 24; 119: e2202012119.
- Koivisto K, Nieminen T, Mejias A, Capella Gonzalez C, Ye F, Mertz S, Peeples M, Ramilo O, Saxén H. Respiratory Syncytial Virus (RSV)-Specific Antibodies in Pregnant Women and Subsequent Risk of RSV Hospitalization in Young Infants. J Infect Dis. 2022 Apr 1; 225: 1189-1196.
- Zeng C, Evans JP, King T, Zheng YM, Oltz EM, Whelan SPJ, Saif LJ, Peeples ME, Liu SL. SARS-CoV-2 spreads through cell-to-cell transmission. Proc Natl Acad Sci U S A. 2022 Jan 4; 119:
- Mertz C, Glowinski R, Cohen SH, Mertz S, Ye F, Hall MW, Peeples ME, King T, Wang H, Leber AL, Sanchez PJ, Ramilo O, Mejias A. Severe Acute Respiratory Syndrome Coronavirus 2 RNAemia and Clinical Outcomes in Children With Coronavirus Disease 2019. J Infect Dis. 2022 Jan 18; 225: 208-213.
- Xue M, Zhang Y, Wang H, Kairis EL, Lu M, Ahmad S, Attia Z, Harder O, Zhang Z, Wei J, Chen P, Gao Y, Peeples ME, Sharma A, Boyaka P, He C, Hur S, Niewiesk S, Li J. Viral RNA N6-methyladenosine modification modulates both innate and adaptive immune responses of human respiratory syncytial virus. PLoS Pathog. 2021 Dec; 17: e1010142.
- Ernzen K, Trask AJ, Peeples ME, Garg V, Zhao MT. Human Stem Cell Models of SARS-CoV-2 Infection in the Cardiovascular System. Stem Cell Rev Rep. 2021 Dec; 17: 2107-2119.
- Hussain SA, Rohlfing M, Resiliac J, Santoro J, Peeples ME, Garcin D, Grayson MH. Atopic Neutrophils Prevent Postviral Airway Disease. J Immunol. 2021 Nov 15; 207: 2589-2597.
- Lu M, Zhang Y, Dravid P, Li A, Zeng C, Kc M, Trivedi S, Sharma H, Chaiwatpongsakorn S, Zani A, Kenney A, Cai C, Ye C, Liang X, Qiu J, Martinez-Sobrido L, Yount JS, Boyaka PN, Liu SL, Peeples ME, Kapoor A, Li J. A Methyltransferase-Defective Vesicular Stomatitis Virus-Based SARS-CoV-2 Vaccine Candidate Provides Complete Protection against SARS-CoV-2 Infection in Hamsters. J Virol. 2021 Sep 27; 95: e0059221.
- Green G, Johnson SM, Costello H, Brakel K, Harder O, Oomens AG, Peeples ME, Moulton HM, Niewiesk S. CX3CR1 Is a Receptor for Human Respiratory Syncytial Virus in Cotton Rats. J Virol. 2021 Jul 26; 95: e0001021.
- King T, Mejias A, Ramilo O, Peeples ME. The larger attachment glycoprotein of respiratory syncytial virus produced in primary human bronchial epithelial cultures reduces infectivity for cell lines. PLoS Pathog. 2021 Apr; 17: e1009469.
- Lu M, Xue M, Wang HT, Kairis EL, Ahmad S, Wei J, Zhang Z, Liu Q, Zhang Y, Gao Y, Garcin D, Peeples ME, Sharma A, Hur S, He C, Li J. Nonsegmented Negative-Sense RNA Viruses Utilize N 6-Methyladenosine (m6A) as a Common Strategy To Evade Host Innate Immunity. J Virol. 2021 Apr 12; 95:
- Cockerill GS, Angell RM, Bedernjak A, Chuckowree I, Fraser I, Gascon-Simorte J, Gilman MSA, Good JAD, Harland R, Johnson SM, Ludes-Meyers JH, Littler E, Lumley J, Lunn G, Mathews N, McLellan JS, Paradowski M, Peeples ME, Scott C, Tait D, Taylor G, Thom M, Thomas E, Villalonga Barber C, Ward SE, Watterson D, Williams G, Young P, Powell K. Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion. J Med Chem. 2021 Apr 8; 64: 3658-3676.
- Lu M, Dravid P, Zhang Y, Trivedi S, Li A, Harder O, Kc M, Chaiwatpongsakorn S, Zani A, Kenney A, Zeng C, Cai C, Ye C, Liang X, Shimamura M, Liu SL, Mejias A, Ramilo O, Boyaka PN, Qiu J, Martinez-Sobrido L, Yount JS, Peeples ME, Kapoor A, Niewiesk S, Li J. A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike. Proc Natl Acad Sci U S A. 2021 Mar 23; 118:
- Binjawadagi B, Ma Y, Binjawadagi R, Brakel K, Harder O, Peeples M, Li J, Niewiesk S. Mucosal Delivery of Recombinant Vesicular Stomatitis Virus Vectors Expressing Envelope Proteins of Respiratory Syncytial Virus Induces Protective Immunity in Cotton Rats. J Virol. 2021 Feb 24; 95:
- Jenkins T, Wang R, Harder O, Xue M, Chen P, Corry J, Walker C, Teng M, Mejias A, Ramilo O, Niewiesk S, Li J, Peeples ME. A Novel Live Attenuated Respiratory Syncytial Virus Vaccine Candidate with Mutations in the L Protein SAM Binding Site and the G Protein Cleavage Site Is Protective in Cotton Rats and a Rhesus Macaque. J Virol. 2021 Jan 13; 95:
- Martinez ME, Capella Gonzalez C, Huey D, Peeples ME, McCarty D, Niewiesk S. Immunogenicity and inflammatory properties of respiratory syncytial virus attachment G protein in cotton rats. PLoS One. 2021; 16: e0246770.
- Xue M, Wang R, Harder O, Chen P, Lu M, Cai H, Li A, Liang X, Jennings R, La Perle K, Niewiesk S, Peeples ME, Li J. Stable Attenuation of Human Respiratory Syncytial Virus for Live Vaccines by Deletion and Insertion of Amino Acids in the Hinge Region between the mRNA Capping and Methyltransferase Domains of the Large Polymerase Protein. J Virol. 2020 Nov 23; 94:
- Abraham RS, Marshall JM, Kuehn HS, Rueda CM, Gibbs A, Guider W, Stewart C, Rosenzweig SD, Wang H, Jean S, Peeples M, King T, Hunt WG, Honegger JR, Ramilo O, Mustillo PJ, Mejias A, Ardura MI, Shimamura M. Severe SARS-CoV-2 Disease In The Context Of A NF?B2 Loss-Of-Function Pathogenic Variant. J Allergy Clin Immunol. 2020 Sep 29;
- Heinonen S, Velazquez VM, Ye F, Mertz S, Acero-Bedoya S, Smith B, Bunsow E, Garcia-Mauriño C, Oliva S, Cohen DM, Moore-Clingenpeel M, Peeples ME, Ramilo O, Mejias A. Immune profiles provide insights into respiratory syncytial virus disease severity in young children. Sci Transl Med. 2020 Apr 22; 12:
- San-Juan-Vergara H, Peeples ME. Importance of Virus Characteristics in Respiratory Syncytial Virus-Induced Disease. Immunol Allergy Clin North Am. 2019 Aug; 39: 321-334.
- Mejias A, Rodriguez-Fernandez R, Peeples ME, Ramilo O. Respiratory Syncytial Virus Vaccines: Are We Making Progress? Pediatr Infect Dis J. 2019 Jul 18;
- Hussain SA, Mejias A, Ramilo O, Peeples ME, Grayson MH. Post-viral atopic airway disease: pathogenesis and potential avenues for intervention. Expert Rev Clin Immunol. 2019 Jan; 15: 49-58.
- Chang SW, Wellmerling J, Zhang X, Rayner RE, Osman W, Mertz S, Amer AO, Peeples ME, Boyaka PN, Cormet-Boyaka E. The psychoactive substance of cannabis ?9-tetrahydrocannabinol (THC) negatively regulates CFTR in airway cells. Biochim Biophys Acta Gen Subj. 2018 Sep; 1862: 1988-1994.
- Li A, Yu J, Lu M, Ma Y, Attia Z, Shan C, Xue M, Liang X, Craig K, Makadiya N, He JJ, Jennings R, Shi PY, Peeples ME, Liu SL, Boyaka PN, Li J. A Zika virus vaccine expressing premembrane-envelope-NS1 polyprotein. Nat Commun. 2018 Aug 3; 9: 3067.
- Grieves JL, Yin Z, Garcia-Sastre A, Mena I, Peeples ME, Risman HP, Federman H, Sandoval MJ, Durbin RK, Durbin JE. A viral-vectored RSV vaccine induces long-lived humoral immunity in cotton rats. Vaccine. 2018 Jun 18; 36: 3842-3852.
Biography
Mark E. Peeples, PhD, is a principal investigator and member of the Center for Vaccines and Immunity at The Research Institute at Nationwide Children’s Hospital, and a professor of Pediatrics and of Molecular & Cellular Biochemistry at The Ohio State University College of Medicine. Dr. Peeples’ research focus is respiratory syncytial virus (RSV) pathogenesis and protection. RSV is the number one cause of hospitalization of children in the developed world and the cause of over 100,000 infant deaths in the developing world, as well as a major cause of death in the elderly, just behind influenza virus. His NIH-funded research is solving the mysteries of the first two steps of RSV infection, attachment and fusion. The two proteins that perform these critical functions are the major targets for vaccine development and for antiviral drug development. Dr. Peeples’ lab is also works with pharmaceutical partners in these endeavors.
Biography
Mark E. Peeples, PhD, is a principal investigator and member of the Center for Vaccines and Immunity at The Research Institute at Nationwide Children’s Hospital, and a professor of Pediatrics and of Molecular & Cellular Biochemistry at The Ohio State University College of Medicine. Dr. Peeples’ research focus is respiratory syncytial virus (RSV) pathogenesis and protection. RSV is the number one cause of hospitalization of children in the developed world and the cause of over 100,000 infant deaths in the developing world, as well as a major cause of death in the elderly, just behind influenza virus. His NIH-funded research is solving the mysteries of the first two steps of RSV infection, attachment and fusion. The two proteins that perform these critical functions are the major targets for vaccine development and for antiviral drug development. Dr. Peeples’ lab is also works with pharmaceutical partners in these endeavors.
Biography
Mark E. Peeples, PhD, is a principal investigator and member of the Center for Vaccines and Immunity at The Research Institute at Nationwide Children’s Hospital, and a professor of Pediatrics and of Molecular & Cellular Biochemistry at The Ohio State University College of Medicine. Dr. Peeples’ research focus is respiratory syncytial virus (RSV) pathogenesis and protection. RSV is the number one cause of hospitalization of children in the developed world and the cause of over 100,000 infant deaths in the developing world, as well as a major cause of death in the elderly, just behind influenza virus. His NIH-funded research is solving the mysteries of the first two steps of RSV infection, attachment and fusion. The two proteins that perform these critical functions are the major targets for vaccine development and for antiviral drug development. Dr. Peeples’ lab is also works with pharmaceutical partners in these endeavors.
Mark E. Peeples, PhD, is a principal investigator and member of the Center for Vaccines and Immunity at The Research Institute at Nationwide Children’s Hospital, and a professor of Pediatrics and of Molecular & Cellular Biochemistry at The Ohio State University College of Medicine. Dr. Peeples’ research focus is respiratory syncytial virus (RSV) pathogenesis and protection. RSV is the number one cause of hospitalization of children in the developed world and the cause of over 100,000 infant deaths in the developing world, as well as a major cause of death in the elderly, just behind influenza virus. His NIH-funded research is solving the mysteries of the first two steps of RSV infection, attachment and fusion. The two proteins that perform these critical functions are the major targets for vaccine development and for antiviral drug development. Dr. Peeples’ lab is also works with pharmaceutical partners in these endeavors.
Mark E. Peeples, PhD, is a principal investigator and member of the Center for Vaccines and Immunity at The Research Institute at Nationwide Children’s Hospital, and a professor of Pediatrics and of Molecular & Cellular Biochemistry at The Ohio State University College of Medicine. Dr. Peeples’ research focus is respiratory syncytial virus (RSV) pathogenesis and protection. RSV is the number one cause of hospitalization of children in the developed world and the cause of over 100,000 infant deaths in the developing world, as well as a major cause of death in the elderly, just behind influenza virus. His NIH-funded research is solving the mysteries of the first two steps of RSV infection, attachment and fusion. The two proteins that perform these critical functions are the major targets for vaccine development and for antiviral drug development. Dr. Peeples’ lab is also works with pharmaceutical partners in these endeavors.
Academic and Clinical Areas
Center for Vaccines and Immunity
Principal Investigator
Primary Department
Center for Vaccines and Immunity
Academic and Clinical Areas
Center for Vaccines and Immunity
Principal Investigator
Primary Department
Center for Vaccines and Immunity
Academic and Clinical Areas
Center for Vaccines and Immunity
Principal Investigator
Primary Department
Center for Vaccines and Immunity
Center for Vaccines and Immunity
Principal Investigator
Primary Department
Center for Vaccines and Immunity
- Center for Vaccines and Immunity
- Principal Investigator
- Primary Department
- Center for Vaccines and Immunity
Professional Experience
2004 - Present Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio,, Professor2004 - Present Center for Vaccines and Immunity, The Research Institute at Nationwide Children’s Hospital, Principal Investigator1993 - 2004 Department of Immunology/Microbiology, Rush Medical College and Division of Immunology, Rush University, Professor1989 - 2004 Section of Virology, Rush Medical College, Rush University, Head1990 - 1998 Department of Immunology/Microbiology, Rush Medical College, Rush University, Associate Chairman1983 - 1998 Department of Immunology/Microbiology, Rush Medical College and Division of Immunology, Graduate College, Rush University, Assistant Professor1995 - 1997 Respiratory Virus Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, Sabbatical1980 - 1993 Department of Molecular Genetics and Microbiology, University of Massachusetts Medical School, Instructor1988 - 1992 Department of Immunology/Microbiology, Rush Medical College and Division of Immunology, Graduate College, Rush University, Associate Professor1988 - 1992 Department of Immunology/Microbiology, Rush Medical College and Division of Immunology, Rush University, Associate Professor1978 - 1980 Department of Molecular Genetics and Microbiology, University of Massachusetts Medical School, Postdoctotal Fellow
Professional Experience
2004 - Present Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio,, Professor2004 - Present Center for Vaccines and Immunity, The Research Institute at Nationwide Children’s Hospital, Principal Investigator1993 - 2004 Department of Immunology/Microbiology, Rush Medical College and Division of Immunology, Rush University, Professor1989 - 2004 Section of Virology, Rush Medical College, Rush University, Head1990 - 1998 Department of Immunology/Microbiology, Rush Medical College, Rush University, Associate Chairman1983 - 1998 Department of Immunology/Microbiology, Rush Medical College and Division of Immunology, Graduate College, Rush University, Assistant Professor1995 - 1997 Respiratory Virus Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, Sabbatical1980 - 1993 Department of Molecular Genetics and Microbiology, University of Massachusetts Medical School, Instructor1988 - 1992 Department of Immunology/Microbiology, Rush Medical College and Division of Immunology, Graduate College, Rush University, Associate Professor1988 - 1992 Department of Immunology/Microbiology, Rush Medical College and Division of Immunology, Rush University, Associate Professor1978 - 1980 Department of Molecular Genetics and Microbiology, University of Massachusetts Medical School, Postdoctotal Fellow
Professional Experience
2004 - Present Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio,, Professor2004 - Present Center for Vaccines and Immunity, The Research Institute at Nationwide Children’s Hospital, Principal Investigator1993 - 2004 Department of Immunology/Microbiology, Rush Medical College and Division of Immunology, Rush University, Professor1989 - 2004 Section of Virology, Rush Medical College, Rush University, Head1990 - 1998 Department of Immunology/Microbiology, Rush Medical College, Rush University, Associate Chairman1983 - 1998 Department of Immunology/Microbiology, Rush Medical College and Division of Immunology, Graduate College, Rush University, Assistant Professor1995 - 1997 Respiratory Virus Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, Sabbatical1980 - 1993 Department of Molecular Genetics and Microbiology, University of Massachusetts Medical School, Instructor1988 - 1992 Department of Immunology/Microbiology, Rush Medical College and Division of Immunology, Graduate College, Rush University, Associate Professor1988 - 1992 Department of Immunology/Microbiology, Rush Medical College and Division of Immunology, Rush University, Associate Professor1978 - 1980 Department of Molecular Genetics and Microbiology, University of Massachusetts Medical School, Postdoctotal Fellow
2004 - Present Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio,, Professor2004 - Present Center for Vaccines and Immunity, The Research Institute at Nationwide Children’s Hospital, Principal Investigator1993 - 2004 Department of Immunology/Microbiology, Rush Medical College and Division of Immunology, Rush University, Professor1989 - 2004 Section of Virology, Rush Medical College, Rush University, Head1990 - 1998 Department of Immunology/Microbiology, Rush Medical College, Rush University, Associate Chairman1983 - 1998 Department of Immunology/Microbiology, Rush Medical College and Division of Immunology, Graduate College, Rush University, Assistant Professor1995 - 1997 Respiratory Virus Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, Sabbatical1980 - 1993 Department of Molecular Genetics and Microbiology, University of Massachusetts Medical School, Instructor1988 - 1992 Department of Immunology/Microbiology, Rush Medical College and Division of Immunology, Graduate College, Rush University, Associate Professor1988 - 1992 Department of Immunology/Microbiology, Rush Medical College and Division of Immunology, Rush University, Associate Professor1978 - 1980 Department of Molecular Genetics and Microbiology, University of Massachusetts Medical School, Postdoctotal Fellow
2004 - Present Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio,, Professor
Contact Information
Center for Vaccines and Immunity
Call us at: (614) 722-3696
Fax us at: (614) 722-3680
Abigail Wexner Research Institute700 Children's Drive, WA4012Columbus, OH 43205 (map)
Contact Information
Center for Vaccines and Immunity
Call us at: (614) 722-3696
Fax us at: (614) 722-3680
Abigail Wexner Research Institute700 Children's Drive, WA4012Columbus, OH 43205 (map)
Contact Information
Center for Vaccines and Immunity
Call us at: (614) 722-3696
Fax us at: (614) 722-3680
Abigail Wexner Research Institute700 Children's Drive, WA4012Columbus, OH 43205 (map)
Center for Vaccines and Immunity
Call us at: (614) 722-3696
Fax us at: (614) 722-3680
Abigail Wexner Research Institute700 Children's Drive, WA4012Columbus, OH 43205 (map)
Call us at: (614) 722-3696
Fax us at: (614) 722-3680
Abigail Wexner Research Institute700 Children's Drive, WA4012Columbus, OH 43205 (map)
Call us at: (614) 722-3696
Fax us at: (614) 722-3680
Abigail Wexner Research Institute700 Children's Drive, WA4012Columbus, OH 43205 (map)
- Call us at:
- (614) 722-3696
- Fax us at:
- (614) 722-3680
- Abigail Wexner Research Institute700 Children’s Drive, WA4012Columbus, OH 43205 (map)